false 0001000228 --12-26 none 480000000 0.01 0.01 1000000 114424682 115771149 Q1 NASDAQ http://fasb.org/us-gaap/2025#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember P5Y P3Y http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember P6Y P10Y P1Y 0001000228 2024-12-29 2025-03-29 0001000228 2025-12-28 2026-03-28 0001000228 2026-03-28 0001000228 2025-12-27 0001000228 us-gaap:RetainedEarningsMember 2025-12-28 2026-03-28 0001000228 2024-12-28 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-28 2026-03-28 0001000228 us-gaap:NoncontrollingInterestMember 2025-12-28 2026-03-28 0001000228 us-gaap:AdditionalPaidInCapitalMember 2025-12-28 2026-03-28 0001000228 us-gaap:CommonStockMember 2025-12-28 2026-03-28 0001000228 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:AssetPledgedAsCollateralMember 2025-12-27 0001000228 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:RecourseMember 2025-12-27 0001000228 us-gaap:EquityMethodInvesteeMember 2025-12-28 2026-03-28 0001000228 us-gaap:EquityMethodInvesteeMember 2024-12-29 2025-03-29 0001000228 hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2025-12-28 2026-03-28 0001000228 us-gaap:EmployeeStockOptionMember 2025-12-28 2026-03-28 0001000228 us-gaap:EmployeeStockOptionMember 2024-12-29 2025-03-29 0001000228 us-gaap:RestrictedStockUnitsRSUMember 2025-12-28 2026-03-28 0001000228 us-gaap:RestrictedStockUnitsRSUMember 2024-12-29 2025-03-29 0001000228 us-gaap:NoncontrollingInterestMember 2025-12-27 0001000228 us-gaap:CommonStockMember 2025-12-27 0001000228 us-gaap:RetainedEarningsMember 2025-12-27 0001000228 us-gaap:AdditionalPaidInCapitalMember 2025-12-27 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-27 0001000228 2025-03-29 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-28 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-27 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2026-03-28 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2025-12-27 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-28 0001000228 us-gaap:FairValueMeasurementsRecurringMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-27 0001000228 us-gaap:FairValueMeasurementsRecurringMember 2025-12-27 0001000228 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:AssetPledgedAsCollateralMember 2026-03-28 0001000228 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:RecourseMember 2026-03-28 0001000228 2026-04-27 0001000228 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-28 0001000228 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-27 0001000228 us-gaap:NoncontrollingInterestMember 2026-03-28 0001000228 us-gaap:CommonStockMember 2026-03-28 0001000228 us-gaap:RetainedEarningsMember 2026-03-28 0001000228 us-gaap:AdditionalPaidInCapitalMember 2026-03-28 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-28 0001000228 us-gaap:EquityMethodInvesteeMember 2025-12-27 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalDentalMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalDentalMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalMedicalMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalMedicalMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalDentalMerchandiseMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalDentalMerchandiseMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalDentalEquipmentMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalDentalEquipmentMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalValueAddedServicesMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalDistributionAndValueAddedServicesMember hsic:GlobalValueAddedServicesMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalSpecialtyProductsMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalSpecialtyProductsMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalTechnologyMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:GlobalTechnologyMember 2024-12-29 2025-03-29 0001000228 hsic:EliminationsAndReconcilingItemsMember 2025-12-28 2026-03-28 0001000228 hsic:EliminationsAndReconcilingItemsMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember 2024-12-29 2025-03-29 0001000228 hsic:GlobalDistributionAndValueAddedServicesMember 2025-12-28 2026-03-28 0001000228 hsic:GlobalDistributionAndValueAddedServicesMember 2024-12-29 2025-03-29 0001000228 hsic:GlobalSpecialtyProductsMember 2025-12-28 2026-03-28 0001000228 hsic:GlobalSpecialtyProductsMember 2024-12-29 2025-03-29 0001000228 hsic:GlobalTechnologyMember 2025-12-28 2026-03-28 0001000228 hsic:GlobalTechnologyMember 2024-12-29 2025-03-29 0001000228 us-gaap:CorporateNonSegmentMember 2025-12-28 2026-03-28 0001000228 us-gaap:CorporateNonSegmentMember 2024-12-29 2025-03-29 0001000228 hsic:OtherShortTermCreditLinesMember 2026-03-28 0001000228 hsic:OtherShortTermCreditLinesMember 2025-12-27 0001000228 us-gaap:LoansPayableMember srt:MinimumMember 2026-03-28 0001000228 us-gaap:LoansPayableMember srt:MaximumMember 2026-03-28 0001000228 us-gaap:LoansPayableMember srt:MinimumMember 2025-12-27 0001000228 us-gaap:LoansPayableMember srt:MaximumMember 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember 2025-12-27 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember 2026-03-28 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember 2025-12-27 0001000228 us-gaap:LoansPayableMember 2026-03-28 0001000228 us-gaap:LoansPayableMember 2025-12-27 0001000228 hsic:TermCreditAgreementMember 2026-03-28 0001000228 hsic:TermCreditAgreementMember 2025-12-27 0001000228 srt:MinimumMember hsic:PrivatePlacementFacilitiesMember 2025-12-28 2026-03-28 0001000228 srt:MaximumMember hsic:PrivatePlacementFacilitiesMember 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember 2025-12-28 2026-03-28 0001000228 hsic:TermCreditAgreementMember 2025-12-28 2026-03-28 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember 2025-12-28 2026-03-28 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember 2024-12-29 2025-12-27 0001000228 srt:MinimumMember hsic:USTradeAccountsReceivableSecuritizationMember 2025-12-28 2026-03-28 0001000228 srt:MaximumMember hsic:USTradeAccountsReceivableSecuritizationMember 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities1Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities2Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities3Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities4Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities5Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities6Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities7Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities8Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities9Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities10Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities1Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities2Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities3Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities4Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities5Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities6Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities7Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities8Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities9Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities10Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities1Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities2Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities3Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities4Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities5Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities6Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities7Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities8Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities9Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities10Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities1Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities2Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities3Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities4Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities5Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities6Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities7Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities8Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities9Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities10Member 2025-12-27 0001000228 us-gaap:RevolvingCreditFacilityMember 2026-03-28 0001000228 us-gaap:RevolvingCreditFacilityMember 2025-12-27 0001000228 us-gaap:RevolvingCreditFacilityMember 2021-08-20 2021-08-20 0001000228 us-gaap:RevolvingCreditFacilityMember 2025-12-28 2026-03-28 0001000228 us-gaap:RevolvingCreditFacilityMember 2024-12-29 2025-12-27 0001000228 srt:MaximumMember hsic:EmployeesAndMinorityShareholdersMember 2026-03-28 0001000228 srt:MinimumMember hsic:EmployeesAndMinorityShareholdersMember 2026-03-28 0001000228 hsic:EmployeesAndMinorityShareholdersMember 2026-03-28 0001000228 hsic:EmployeesAndMinorityShareholdersMember 2025-12-27 0001000228 hsic:EmployeesAndMinorityShareholdersMember hsic:OperatingLeaseLiabilitiesCurrentMember hsic:RelatedPartyConcentrationRiskMember 2025-12-28 2026-03-28 0001000228 hsic:EmployeesAndMinorityShareholdersMember hsic:OperatingLeaseLiabilitiesNoncurrentMember hsic:RelatedPartyConcentrationRiskMember 2025-12-28 2026-03-28 0001000228 us-gaap:EquityMethodInvesteeMember 2026-03-28 0001000228 us-gaap:InvestorMember 2026-03-28 0001000228 hsic:June2026ThroughJune2027Member 2025-12-28 2026-03-28 0001000228 hsic:September2027ThroughJune2030Member 2025-12-28 2026-03-28 0001000228 hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember 2025-12-28 2026-03-28 0001000228 us-gaap:InvestorMember 2025-05-16 0001000228 2025-05-19 0001000228 2025-05-01 2025-05-31 0001000228 hsic:TermCreditAgreementMember 2024-12-29 2025-06-05 0001000228 hsic:InternetBrandsIncMember hsic:HenryScheinOneMember 2018-04-03 0001000228 hsic:InternetBrandsIncMember hsic:HenryScheinOneMember 2026-03-28 0001000228 us-gaap:CoVenturerMember hsic:InternetBrandsIncMember 2025-12-28 2026-03-28 0001000228 srt:AffiliatedEntityMember hsic:InternetBrandsIncMember hsic:HenryScheinOneLLCMember 2026-03-28 0001000228 srt:AffiliatedEntityMember hsic:InternetBrandsIncMember hsic:HenryScheinOneLLCMember 2025-12-27 0001000228 us-gaap:RoyaltyAgreementsMember us-gaap:CoVenturerMember hsic:InternetBrandsIncMember 2025-12-28 2026-03-28 0001000228 us-gaap:RoyaltyAgreementsMember us-gaap:CoVenturerMember hsic:InternetBrandsIncMember 2024-12-29 2025-03-29 0001000228 us-gaap:CommonStockMember 2024-12-28 0001000228 us-gaap:CommonStockMember 2025-03-29 0001000228 us-gaap:CommonStockMember 2024-12-29 2025-03-29 0001000228 us-gaap:AdditionalPaidInCapitalMember 2024-12-28 0001000228 us-gaap:AdditionalPaidInCapitalMember 2024-12-29 2025-03-29 0001000228 us-gaap:AdditionalPaidInCapitalMember 2025-03-29 0001000228 us-gaap:RetainedEarningsMember 2024-12-28 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-28 0001000228 us-gaap:NoncontrollingInterestMember 2024-12-28 0001000228 us-gaap:RetainedEarningsMember 2024-12-29 2025-03-29 0001000228 us-gaap:NoncontrollingInterestMember 2024-12-29 2025-03-29 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 2025-03-29 0001000228 us-gaap:RetainedEarningsMember 2025-03-29 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-29 0001000228 us-gaap:NoncontrollingInterestMember 2025-03-29 0001000228 2025-07-01 2025-07-31 0001000228 us-gaap:IntersegmentEliminationMember 2025-12-28 2026-03-28 0001000228 us-gaap:IntersegmentEliminationMember 2024-12-29 2025-03-29 0001000228 us-gaap:IntersegmentEliminationMember hsic:GlobalDistributionAndValueAddedServicesMember 2025-12-28 2026-03-28 0001000228 us-gaap:IntersegmentEliminationMember hsic:GlobalDistributionAndValueAddedServicesMember 2024-12-29 2025-03-29 0001000228 us-gaap:IntersegmentEliminationMember hsic:GlobalSpecialtyProductsMember 2025-12-28 2026-03-28 0001000228 us-gaap:IntersegmentEliminationMember hsic:GlobalSpecialtyProductsMember 2024-12-29 2025-03-29 0001000228 us-gaap:IntersegmentEliminationMember hsic:GlobalTechnologyMember 2025-12-28 2026-03-28 0001000228 us-gaap:IntersegmentEliminationMember hsic:GlobalTechnologyMember 2024-12-29 2025-03-29 0001000228 hsic:Acquisitions2026Member 2025-12-28 2026-03-28 0001000228 hsic:Acquisitions2025Member 2025-12-28 2026-03-28 0001000228 hsic:Acquisitions2026Member 2026-03-28 0001000228 hsic:Acquisitions2025Member 2026-03-28 0001000228 hsic:CustomerRelationshipsAndListsMember hsic:Acquisitions2026Member 2025-12-28 2026-03-28 0001000228 us-gaap:TrademarksAndTradeNamesMember hsic:Acquisitions2026Member 2025-12-28 2026-03-28 0001000228 hsic:CustomerRelationshipsAndListsMember hsic:Acquisitions2025Member 2024-12-29 2025-12-27 0001000228 us-gaap:TrademarksAndTradeNamesMember hsic:Acquisitions2025Member 2024-12-29 2025-12-27 0001000228 hsic:ProductDevelopmentMember hsic:Acquisitions2025Member 2024-12-29 2025-12-27 0001000228 us-gaap:NoncompeteAgreementsMember hsic:Acquisitions2025Member 2024-12-29 2025-12-27 0001000228 hsic:Acquisitions2025Member 2024-12-29 2025-12-27 0001000228 hsic:AcquisitionsOfControllingInterestsOfAffiliatesMember 2025-12-28 2026-03-28 0001000228 srt:MinimumMember hsic:Acquisitions2025Member 2025-12-27 0001000228 srt:MaximumMember hsic:Acquisitions2025Member 2025-12-27 0001000228 hsic:Acquisitions2023Member 2025-12-28 2026-03-28 0001000228 hsic:Acquisitions2023Member 2024-12-29 2025-03-29 0001000228 hsic:OtherShortTermCreditLinesMember 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities11Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities12Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities13Member 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities11Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities12Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities13Member 2025-12-28 2026-03-28 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities11Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities12Member 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities11Member 2024-12-29 2025-12-27 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities12Member 2024-12-29 2025-12-27 0001000228 hsic:TermCreditAgreementMember 2024-12-29 2025-12-27 0001000228 hsic:Plan2024Member 2025-12-28 2026-03-28 0001000228 hsic:Plan2024Member 2024-12-29 2025-03-29 0001000228 hsic:EmployeesAndMinorityShareholdersMember hsic:OperatingLeaseLiabilitiesCurrentMember hsic:RelatedPartyConcentrationRiskMember 2024-12-29 2025-12-27 0001000228 hsic:EmployeesAndMinorityShareholdersMember hsic:OperatingLeaseLiabilitiesNoncurrentMember hsic:RelatedPartyConcentrationRiskMember 2024-12-29 2025-12-27 0001000228 us-gaap:InvestorMember 2025-05-16 2025-05-16 0001000228 us-gaap:InvestorMember srt:MaximumMember 2025-01-29 0001000228 srt:ChiefExecutiveOfficerMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member 2025-12-28 2026-03-28 0001000228 srt:ChiefExecutiveOfficerMember hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member 2025-12-28 2026-03-28 0001000228 us-gaap:EmployeeStockOptionMember srt:ChiefExecutiveOfficerMember hsic:PlanYear2026Member 2025-12-28 2026-03-28 0001000228 srt:ChiefExecutiveOfficerMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026SignOnMember 2025-12-28 2026-03-28 0001000228 srt:ChiefExecutiveOfficerMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member 2025-12-28 2026-03-28 0001000228 srt:ChiefExecutiveOfficerMember hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member 2025-12-28 2026-03-28 0001000228 us-gaap:ExecutiveCommitteeMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member 2025-12-28 2026-03-28 0001000228 us-gaap:ExecutiveCommitteeMember hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member 2025-12-28 2026-03-28 0001000228 us-gaap:ExecutiveCommitteeMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member 2025-12-28 2026-03-28 0001000228 us-gaap:ExecutiveCommitteeMember hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member 2025-12-28 2026-03-28 0001000228 srt:VicePresidentMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member 2025-12-28 2026-03-28 0001000228 srt:VicePresidentMember hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member 2025-12-28 2026-03-28 0001000228 srt:VicePresidentMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member 2025-12-28 2026-03-28 0001000228 srt:VicePresidentMember hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member 2025-12-28 2026-03-28 0001000228 srt:DirectorMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member 2025-12-28 2026-03-28 0001000228 srt:DirectorMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member 2025-12-28 2026-03-28 0001000228 srt:VicePresidentMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member hsic:ThirdYearMember 2025-12-28 2026-03-28 0001000228 srt:VicePresidentMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member hsic:FourthYearMember 2025-12-28 2026-03-28 0001000228 srt:DirectorMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member hsic:ThirdYearMember 2025-12-28 2026-03-28 0001000228 srt:DirectorMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2025Member hsic:FourthYearMember 2025-12-28 2026-03-28 0001000228 hsic:NonEmployeeDirectorStockIncentivePlanMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2025-12-28 2026-03-28 0001000228 hsic:EmployeeStockIncentivePlanMember hsic:NonQualifiedStockOptionsMember 2025-12-28 2026-03-28 0001000228 hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2024-12-29 2025-03-29 0001000228 hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember 2024-12-29 2025-03-29 0001000228 hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2025-12-27 0001000228 hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember 2025-12-27 0001000228 hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2026-03-28 0001000228 hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember 2026-03-28 0001000228 srt:ChiefExecutiveOfficerMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member hsic:PerYearMember 2025-12-28 2026-03-28 0001000228 us-gaap:EmployeeStockOptionMember srt:ChiefExecutiveOfficerMember hsic:PlanYear2026Member hsic:PerYearMember 2025-12-28 2026-03-28 0001000228 srt:ChiefExecutiveOfficerMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026SignOnMember hsic:PerYearMember 2025-12-28 2026-03-28 0001000228 us-gaap:ExecutiveCommitteeMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member hsic:PerYearMember 2025-12-28 2026-03-28 0001000228 srt:VicePresidentMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member hsic:PerYearMember 2025-12-28 2026-03-28 0001000228 srt:DirectorMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember hsic:PlanYear2026Member hsic:PerYearMember 2025-12-28 2026-03-28 0001000228 us-gaap:InvestorMember srt:MaximumMember 2025-11-04 0001000228 srt:MinimumMember hsic:Acquisitions2026Member 2026-03-28 0001000228 srt:MaximumMember hsic:Acquisitions2026Member 2026-03-28 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:TotalReturnSwapMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:TotalReturnSwapMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:TotalReturnSwapMember 2026-03-28 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:TotalReturnSwapMember 2026-03-28 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:TotalReturnSwapMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:TotalReturnSwapMember 2025-12-27 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:TotalReturnSwapMember 2025-12-27 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:TotalReturnSwapMember 2025-12-27 0001000228 us-gaap:OperatingSegmentsMember hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member hsic:GlobalTechnologyMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalTechnologyMember hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member hsic:GlobalTechnologyMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:LossOnDisposalOfBusinessMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:LossOnDisposalOfBusinessMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:LossOnDisposalOfBusinessMember hsic:Plan2024Member hsic:GlobalTechnologyMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalTechnologyMember 2025-12-28 2026-03-28 0001000228 us-gaap:OperatingSegmentsMember hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member hsic:GlobalTechnologyMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalTechnologyMember hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member hsic:GlobalTechnologyMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalDistributionAndValueAddedServicesMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember 2024-12-29 2025-03-29 0001000228 us-gaap:OperatingSegmentsMember hsic:Plan2024Member hsic:GlobalTechnologyMember 2024-12-29 2025-03-29 0001000228 us-gaap:CorporateNonSegmentMember hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member 2024-12-29 2025-03-29 0001000228 us-gaap:CorporateNonSegmentMember hsic:Plan2024Member hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2024-12-29 2025-03-29 0001000228 us-gaap:CorporateNonSegmentMember hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member 2024-12-29 2025-03-29 0001000228 us-gaap:CorporateNonSegmentMember hsic:Plan2024Member 2024-12-29 2025-03-29 0001000228 hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member 2024-12-29 2025-03-29 0001000228 hsic:Plan2024Member hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2024-12-29 2025-03-29 0001000228 hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member 2024-12-29 2025-03-29 0001000228 us-gaap:CorporateNonSegmentMember hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member 2025-12-28 2026-03-28 0001000228 us-gaap:CorporateNonSegmentMember hsic:Plan2024Member hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2025-12-28 2026-03-28 0001000228 us-gaap:CorporateNonSegmentMember hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member 2025-12-28 2026-03-28 0001000228 us-gaap:CorporateNonSegmentMember hsic:LossOnDisposalOfBusinessMember hsic:Plan2024Member 2025-12-28 2026-03-28 0001000228 us-gaap:CorporateNonSegmentMember hsic:Plan2024Member 2025-12-28 2026-03-28 0001000228 hsic:SeveranceAndEmployeeRelatedCostsMember hsic:Plan2024Member 2025-12-28 2026-03-28 0001000228 hsic:Plan2024Member hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember 2025-12-28 2026-03-28 0001000228 hsic:ExitAndOtherRelatedCostsMember hsic:Plan2024Member 2025-12-28 2026-03-28 0001000228 hsic:LossOnDisposalOfBusinessMember hsic:Plan2024Member 2025-12-28 2026-03-28 0001000228 hsic:LossOnDisposalOfBusinessMember hsic:Plan2024Member hsic:GlobalSpecialtyProductsMember 2025-12-28 2026-03-28 0001000228 hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember hsic:EmployeeStockIncentivePlanMember 2025-12-28 2026-03-28 iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares hsic:number hsic:segments
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the
quarterly
period ended
March 28, 2026
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT
OF 1934
For the transition period from ____________ to ____________
Commission File Number:
0-27078
HENRY SCHEIN, INC.
(Exact name of registrant as specified in its charter)
Delaware
11-3136595
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
135 Duryea Road
Melville
,
New York
(Address of principal executive offices)
11747
(Zip Code)
(
631
)
843-5500
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.01 per share
HSIC
The
Nasdaq
Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every
Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during
the preceding 12 months (or for such shorter period
that the registrant was required to submit such files).
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,”
“accelerated filer,”
“smaller reporting company,”
and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for
complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).
Yes
No
As of April 27, 2026,
there were
113,916,757
shares of the registrant’s common stock outstanding.
HENRY SCHEIN, INC.
INDEX
Page
3
4
5
6
7
8
8
9
10
11
14
17
20
23
24
25
26
29
30
31
31
32
33
34
47
48
49
49
49
50
51
See accompanying notes.
3
PART
I. FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share data)
March 28,
December 27,
2026
2025
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
138
$
156
Accounts receivable, net of allowance for credit losses of $
96
and $
90
(1)
1,719
1,651
Inventories, net
2,014
2,002
Prepaid expenses and other
625
655
Total current assets
4,496
4,464
Property and equipment, net
618
621
Operating lease right-of-use assets
312
301
Goodwill
4,284
4,213
Other intangibles, net
1,007
1,018
Investments and other
587
598
Total assets
$
11,304
$
11,215
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND
STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
1,043
$
1,154
Bank credit lines
1,046
764
Current maturities of long-term debt
35
33
Operating lease liabilities
78
78
Accrued expenses:
Payroll and related
262
340
Taxes
192
179
Other
641
680
Total current liabilities
3,297
3,228
Long-term debt (1)
2,327
2,310
Deferred income taxes
158
146
Operating lease liabilities
263
251
Other liabilities
437
486
Total liabilities
6,482
6,421
Redeemable noncontrolling interests
903
895
Commitments and contingencies
(nil)
(nil)
Stockholders' equity:
Preferred stock, $
0.01
par value,
1,000,000
shares authorized,
none
outstanding
-
-
Common stock, $
0.01
par value,
480,000,000
shares authorized,
114,424,682
issued and outstanding on March 28, 2026 and
115,771,149
issued and outstanding on December 27, 2025
1
1
Additional paid-in capital
167
177
Retained earnings
3,287
3,293
Accumulated other comprehensive loss
(189)
(226)
Total Henry Schein, Inc. stockholders' equity
3,266
3,245
Noncontrolling interests
653
654
Total stockholders' equity
3,919
3,899
Total liabilities, redeemable noncontrolling
interests and stockholders' equity
$
11,304
$
11,215
(1)
Amounts presented include balances held by our consolidated variable interest entity (“VIE”).
At March 28, 2026 and December
27, 2025, includes trade accounts receivable of $
442
million and $
491
million, respectively, and long-term debt of $
360
million and
$
390
million, respectively.
See
for further information.
See accompanying notes.
4
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF INCOME
(in millions,
except share and per share data)
(unaudited)
Three Months Ended
March 28,
March 29,
2026
2025
Net sales
$
3,368
$
3,168
Cost of sales
2,298
2,168
Gross profit
1,070
1,000
Operating expenses:
Selling, general and administrative
809
738
Depreciation and amortization
67
62
Restructuring and related costs
12
25
Operating income
182
175
Other income (expense):
Interest income
7
6
Interest expense
(39)
(35)
Other, net
-
(1)
Income before taxes, equity in earnings of affiliates and noncontrolling interests
150
145
Income taxes
(38)
(35)
Equity in earnings of affiliates, net of tax
-
3
Net income
112
113
Less: Net income attributable to noncontrolling interests
(5)
(3)
Net income attributable to Henry Schein, Inc.
$
107
$
110
Earnings per share attributable to Henry Schein, Inc.:
Basic
$
0.93
$
0.89
Diluted
$
0.92
$
0.88
Weighted-average common
shares outstanding:
Basic
114,939,640
123,776,073
Diluted
116,061,244
124,848,221
See accompanying notes.
5
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF COMPREHENSIVE INCOME
(in millions)
(unaudited)
Three Months Ended
March 28,
March 29,
2026
2025
Net income
$
112
$
113
Other comprehensive income, net of tax:
Foreign currency translation gain
32
76
Unrealized gain (loss) from hedging activities
8
(5)
Other comprehensive income, net of tax
40
71
Comprehensive income
152
184
Comprehensive income attributable to noncontrolling interests:
Net income
(5)
(3)
Foreign currency translation gain
(3)
(9)
Comprehensive income attributable to noncontrolling interests
(8)
(12)
Comprehensive income attributable to Henry Schein, Inc.
$
144
$
172
See accompanying notes.
6
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF CHANGES IN
STOCKHOLDERS’ EQUITY
(in millions, except share data)
(unaudited)
Accumulated
Common Stock
Additional
Other
Total
$0.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income (Loss)
Interests
Equity
Balance, December 27, 2025
115,771,149
$
1
$
177
$
3,293
$
(226)
$
654
$
3,899
Net income (excluding loss of $
1
attributable to Redeemable
noncontrolling interests)
-
-
-
107
-
6
113
Foreign currency translation gain (excluding gain of $
3
attributable to Redeemable noncontrolling interests)
-
-
-
-
29
-
29
Unrealized gain from hedging activities,
net of tax of $
3
-
-
-
-
8
-
8
Distributions from noncontrolling shareholders
-
-
-
-
-
(7)
(7)
Change in fair value of redeemable securities
-
-
(18)
-
-
-
(18)
Noncontrolling interests and adjustments related to
business acquisitions and contingent consideration
-
-
28
-
-
-
28
Repurchase and retirement of common stock
(1,609,986)
-
(13)
(113)
-
-
(126)
Stock issued upon exercise of stock options
16,570
-
1
-
-
-
1
Stock-based compensation expense
383,040
-
3
-
-
-
3
Shares withheld for payroll taxes
(132,834)
-
(11)
-
-
-
(11)
Settlement of stock-based compensation awards
(3,257)
-
-
-
-
-
-
Balance, March 28, 2026
114,424,682
$
1
$
167
$
3,287
$
(189)
$
653
$
3,919
Accumulated
Common Stock
Additional
Other
Total
$0.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income (Loss)
Interests
Equity
Balance, December 28, 2024
124,155,884
$
1
$
-
$
3,771
$
(379)
$
638
$
4,031
Net income (excluding loss of $
2
attributable to Redeemable
noncontrolling interests)
-
-
-
110
-
5
115
Foreign currency translation gain (excluding gain of $
8
attributable to Redeemable noncontrolling interests)
-
-
-
-
67
1
68
Unrealized loss from hedging activities,
net of tax benefit of $
1
-
-
-
-
(5)
-
(5)
Pension adjustment gain, net of tax of $
1
-
-
-
-
-
-
-
Change in fair value of redeemable securities
-
-
(28)
-
-
-
(28)
Noncontrolling interests and adjustments related to
business acquisitions and contingent consideration
-
-
(60)
-
-
-
(60)
Repurchase and retirement of common stock
(2,255,485)
-
(21)
(141)
-
-
(162)
Stock issued upon exercise of stock options
10,351
-
1
-
-
-
1
Stock-based compensation expense
520,385
-
5
-
-
-
5
Shares withheld for payroll taxes
(187,493)
-
(11)
-
-
-
(11)
Settlement of stock-based compensation awards
41
-
-
-
-
-
-
Transfer of charges in excess of
capital
-
-
114
(114)
-
-
-
Balance, March 29, 2025
122,243,683
$
1
$
-
$
3,626
$
(317)
$
644
$
3,954
See accompanying notes.
7
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS
(in millions)
(unaudited)
Three Months Ended
March 28,
March 29,
2026
2025
Cash flows from operating activities:
Net income
$
112
$
113
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization
81
73
Impairment charge on intangible assets
-
1
Non-cash restructuring and related charges
2
1
Stock-based compensation expense
3
5
Provision for losses on trade and other accounts receivable
6
2
Provision for (benefit from) deferred income taxes
2
(7)
Equity in earnings of affiliates
-
(3)
Distributions from equity affiliates
3
2
Changes in unrecognized tax benefits
(1)
2
Other
(27)
(27)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable
(69)
(74)
Inventories
8
(14)
Other current assets
6
75
Accounts payable and accrued expenses
(223)
(112)
Net cash provided by (used in) operating activities
(97)
37
Cash flows from investing activities:
Purchases of property and equipment
(25)
(31)
Payments related to equity investments and business acquisitions,
net of cash acquired
(24)
(51)
Proceeds from loan to affiliate
1
-
Capitalized software costs
(14)
(12)
Other
(1)
(5)
Net cash used in investing activities
(63)
(99)
Cash flows from financing activities:
Net change in bank credit lines
283
215
Proceeds from issuance of long-term debt
57
150
Principal payments for long-term debt
(39)
(15)
Proceeds from issuance of stock upon exercise of stock options
1
1
Payments for repurchases and retirement of common stock
(125)
(161)
Payments for taxes related to shares withheld for employee taxes
(9)
(12)
Distributions to noncontrolling shareholders
(16)
(4)
Payments for contingent consideration
-
(12)
Acquisitions of noncontrolling interests in subsidiaries
(32)
(73)
Net cash provided by financing activities
120
89
Effect of exchange rate changes on cash and cash equivalents
22
(22)
Net change in cash and cash equivalents
(18)
5
Cash and cash equivalents, beginning of period
156
122
Cash and cash equivalents, end of period
$
138
$
127
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
8
Note 1 – Basis of Presentation
Our condensed consolidated financial statements include the accounts of Henry
Schein, Inc. and all of our
controlled subsidiaries and VIE (“we,” “us” and “our”).
All intercompany accounts and transactions are eliminated
in consolidation.
Investments in unconsolidated affiliates for which we have the ability to influence
the operating
or financial decisions are accounted for under the equity method.
Our accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with
accounting principles generally accepted in the United States
(“U.S. GAAP”) for interim financial information and
with the instructions to Form 10-Q and Article 10 of Regulation S-X.
Accordingly, they do not include all of the
information and footnote disclosures required by U.S. GAAP for complete
financial statements.
The unaudited condensed consolidated financial statements should
be read in conjunction with the audited
consolidated financial statements and notes to the consolidated financial
statements contained in our Annual Report
on Form 10-K for the year ended December 27, 2025 and with the information
contained in our other publicly-
available filings with the Securities and Exchange Commission.
The condensed consolidated financial statements
reflect all adjustments considered necessary for a fair presentation of
the consolidated results of operations and
financial position for the interim periods presented.
All such adjustments are of a normal recurring nature.
The preparation of consolidated financial statements in conformity with
accounting principles generally accepted in
the United States requires us to make estimates and assumptions that
affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported
amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
The results of operations for the three months ended March 28, 2026 are
not necessarily indicative of the results to
be expected for any other interim period or for the year ending December 26, 2026.
Our condensed consolidated financial statements reflect estimates and
assumptions made by us that affect, among
other things, our goodwill, long-lived asset and definite-lived intangible
asset valuation; inventory valuation; equity
investment valuation; assessment of the annual effective tax rate; valuation of
deferred income taxes and income
tax contingencies; the allowance for credit losses; fair value of contingent
consideration; hedging activity; supplier
rebates; measurement of compensation cost for certain share-based
performance awards and cash bonus plans; and
pension plan assumptions.
The primary beneficiary of a VIE is required to consolidate the assets and
liabilities of the VIE.
We are deemed to
be the primary beneficiary of the VIE when we have the power to direct activities
that most significantly affect its
economic performance and have the obligation to absorb the majority of
its losses or the right to receive benefits
that could potentially be significant to the VIE.
In determining whether we are the primary beneficiary, we
consider factors such as ownership interest, debt investments, management
representation, authority to control
decisions, and contractual and substantive participating rights of each party.
For this VIE, related to our U.S. trade
accounts receivable securitization as discussed in
,
the trade accounts receivable transferred to the
VIE are pledged as collateral to the related debt.
The VIE’s creditors have recourse to us for losses on these trade
accounts receivable.
At March 28, 2026 and December 27, 2025, certain trade accounts
receivable that can only be
used to settle obligations of this VIE were $
442
million and $
491
million, respectively, and the liabilities of this
VIE where the creditors have recourse to us were $
360
million and $
390
million, respectively.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
9
Note 2 – Significant Accounting Policies,
Accounting Pronouncements Recently Adopted and Recently
Issued
Accounting Pronouncements
Significant Accounting Policies
There have been no material changes in our significant accounting policies during
the three months ended March
28, 2026, as compared to the significant accounting policies described in Item
8 of our Annual Report on Form 10-
K for the year ended December 27, 2025.
Accounting Pronouncements Recently Adopted
In July 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2025-05, “
Financial Instruments - Credit Losses (Subtopic 326): Measurement of Credit Losses for Accounts
Receivable and Contract Assets,
” which introduces a practical expedient permitting an entity
to assume that
conditions at the balance sheet date remain unchanged throughout the
remaining life of the asset when estimating
expected credit losses on current accounts receivable and current contract
assets under Topic 606 -
Revenue from
Contracts with Customers
.
We adopted this ASU during fiscal year 2026 and elected to apply the practical
expedient.
The adoption did not have a material impact on our consolidated financial
statements.
Recently Issued Accounting Pronouncements
In December 2025, the FASB issued ASU 2025-11, “
Interim Reporting (Topic 270): Narrow-Scope
Improvements
,” which is intended to improve navigability of the guidance in Topic 270, Interim Reporting, and
clarify when it applies.
The ASU also addresses the form and content of such financial
statements and interim
disclosure requirements, and establishes a principle under which an entity
must disclose events since the end of the
last annual reporting period that have a material impact on the entity.
This ASU is effective for annual reporting
periods beginning after December 15, 2027, and interim reporting periods
within those annual reporting periods,
with early adoption permitted.
We are currently evaluating the impact that ASU 2025-11 will have on our
consolidated financial statements and related disclosures.
In December 2025, the FASB issued ASU 2025-10, “
Government Grants (Topic 832) - Accounting for Government
Grants Received by Business Entities,
” which establishes guidance on the recognition, measurement, and
presentation of government grants received by business entities.
This ASU is effective for annual reporting periods
beginning after December 15, 2028, and interim reporting periods within
those annual reporting periods, with early
adoption permitted.
We are currently evaluating the impact that ASU 2025-10 will have on our consolidated
financial statements and related disclosures.
In November 2025, the FASB issued ASU 2025-09, “
Derivatives and Hedging (Topic 815): Hedge Accounting
Improvements,
” which is intended to more closely align financial reporting with
the economics of entities’ risk
management activities, including expanded eligibility of forecasted
transactions, additional flexibility in measuring
hedge effectiveness, and clarifications related to hedging non-financial items.
This ASU is effective for annual
reporting periods beginning after December 15, 2026, and interim reporting
periods within those annual reporting
periods, with early adoption permitted, and should be applied prospectively.
We are currently evaluating the
impact that ASU 2025-09 will have on our consolidated financial statements
and related disclosures.
In September 2025, the FASB issued ASU 2025-06, “
Intangibles - Goodwill and Other - Internal-Use Software
(Subtopic 350-40): Targeted Improvements
to the Accounting for Internal-Use Software
,” which removes all
references to software development project stages.
The ASU requires entities to begin capitalizing software costs
when management authorizes and commits to funding the software project,
and it is probable that the project will
be completed and the software will be used for its intended purpose.
This ASU is effective for annual reporting
periods beginning after December 15, 2027, and interim reporting periods
within those annual reporting periods,
with early adoption permitted.
Upon adoption, the guidance can be applied prospectively, retrospectively, or with a
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
10
modified transition approach.
We are currently evaluating the impact that ASU 2025-06 will have on our
consolidated financial statements.
Note 3 – Net Sales from Contracts with Customers
Net sales are recognized in accordance with policies disclosed in Item
8 of our Annual Report on Form 10-K for
the year ended December 27, 2025.
Disaggregation of Net Sales
The following table disaggregates our net sales by reportable segment:
Three Months Ended
March 28,
March 29,
2026
2025
Net Sales:
Global Distribution and Value
-Added Services
Global Dental merchandise
$
1,292
$
1,185
Global Dental equipment
417
384
Global Value
-added services
57
52
Global Dental
1,766
1,621
Global Medical
1,073
1,055
Total Global Distribution
and Value
-Added Services
2,839
2,676
Global Specialty Products
397
367
Global Technology
173
162
Eliminations
(41)
(37)
Total
$
3,368
$
3,168
Contract Liabilities
The following table presents our contract liabilities:
As of
March 28,
December 27,
March 29,
December 28,
Description
2026
2025
2025
2024
Current contract liabilities
$
84
$
81
$
85
$
81
Non-current contract liabilities
9
9
7
8
Total contract
liabilities
$
93
$
90
$
92
$
89
During the three months ended March 28, 2026, we recognized $
35
million in net sales that had been previously
deferred at December 27, 2025.
During the three months ended March 29, 2025, we recognized $
34
million in net
sales that were previously deferred at December 28, 2024.
Current contract liabilities are included in accrued
expenses: other and the non-current contract liabilities are included in other
liabilities within our condensed
consolidated balance sheets.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
11
Note 4
Segment Data
We conduct our business through
three
reportable segments: (i) Global Distribution and Value-Added Services; (ii)
Global Specialty Products; and (iii) Global Technology.
We aggregate operating segments into these reportable segments based on economic similarities, the nature of their
products, customer base and methods of distribution.
Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of
national brand and corporate brand merchandise, as well as equipment and related
technical services.
This segment
also includes value-added services such as financial services, continuing
education services, consulting and other
services.
This segment also markets and sells under our own corporate brand
a portfolio of cost-effective, high-
quality consumable merchandise.
Global Specialty Products includes manufacturing, marketing
and sales of dental
implant and biomaterial products; and endodontic, orthodontic and orthopedic
products and other health care-
related products and services.
Global Technology includes development and distribution of practice management
software, e-services and other products, which are distributed to health
care providers.
Our organizational structure also includes Corporate, which consists primarily of
income and expenses associated
with support functions and projects.
Our chief operating decision maker (“CODM”) is our Chief Executive
Officer (“CEO”).
Our CODM uses adjusted
operating income as the profitability metric for purposes of making decisions
about allocation of resources to each
segment and assessing performance of each segment.
Adjusted operating income provides a measure of our
underlying segment results that is in line with our approach to risk and performance
management.
We define
adjusted operating income as operating income adjusted to exclude
(a) direct cybersecurity costs and related
insurance recovery proceeds, (b) amortization of acquisition intangibles,
(c) organizational restructuring and related
expenses, (d) impairment of intangible assets, (e) changes in fair value of
contingent consideration, (f) litigation
settlements, and (g) costs associated with shareholder advisory
matters and select implementation related value
creation consulting costs.
These adjustments are either: (i) non-cash or non-recurring in nature; (ii) not
allocable or
controlled by the segment; or (iii) not tied to the operational performance
of the segment.
Assets by segment are
not a measure used to assess the performance of the Company by CODM and
thus are not reported in our
disclosures.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
12
Segment adjusted operating income is presented in the following
table to reconcile to operating income as
presented on the condensed consolidated statement of operations.
The reconciliation from operating income to
income before taxes and equity in earnings of affiliates is presented on our condensed consolidated
statements of
income.
Three Months Ended
March 28,
March 29,
2026
2025
Gross Sales:
Global Distribution and Value
-Added Services
(1)
$
2,839
$
2,676
Global Specialty Products
(2)
397
367
Global Technology
(3)
173
162
Total Gross Sales
3,409
3,205
Less: Eliminations:
Global Distribution and Value
-Added Services
(3)
(4)
Global Specialty Products
(38)
(33)
Global Technology
-
-
Total Eliminations
(41)
(37)
Net Sales:
Global Distribution and Value
-Added Services
2,836
2,672
Global Specialty Products
359
334
Global Technology
173
162
Total Net Sales
3,368
3,168
Segment Cost of Sales:
(4)
Global Distribution and Value
-Added Services
2,107
1,995
Global Specialty Products
177
161
Global Technology
54
52
Segment Operating Expenses:
(5)
Global Distribution and Value
-Added Services
549
514
Global Specialty Products
162
150
Global Technology
73
68
Operating Income:
Global Distribution and Value
-Added Services
183
167
Global Specialty Products
58
56
Global Technology
46
42
Total Segment Operating Income
287
265
Corporate, net
(34)
(35)
Adjustments
(6)
(71)
(55)
Total Operating Income
$
182
$
175
Three Months Ended
March 28,
March 29,
2026
2025
Depreciation and Amortization:
Global Distribution and Value
-Added Services
$
7
$
6
Global Specialty Products
9
8
Global Technology
10
8
Total Segment Depreciation and Amortization
26
22
Corporate
10
8
Acquisition intangible amortization within adjustments
(6)
45
43
Total Depreciation and Amortization
$
81
$
73
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
13
(1)
Global Distribution and Value
-Added Services: Includes distribution of infection-control products, handpieces, preventatives,
impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, personal protective equipment
(“PPE”) products,
branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units
and lights, digital dental laboratories, X-ray supplies and equipment, high-tech and digital restoration equipment, equipment repair
services, financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.
This segment also markets and sells under our own corporate brand a portfolio of cost-effective, high-quality consumable
merchandise.
(2)
Global Specialty Products: Includes manufacturing, marketing and sales of dental implant and biomaterial products; and
endodontic, orthodontic and orthopedic products and other health care-related products and services.
(3)
Global Technology: Includes development and distribution of practice management software, e-services and other products, which
are distributed to health care providers.
(4)
Cost of goods sold in our Global Distribution and Value-Added Services segment and our Global Specialty Products segment
includes product cost and inbound and outbound freight charges.
Cost of goods sold in our Global Technology segment consists
primarily of software development and third-party provider costs, including technology use and hosting fees.
(5)
Significant segment operating expenses for our reportable segments and Corporate include primarily compensation costs, and to a
lesser extent, rent, depreciation and maintenance costs related to operating our facilities.
(6)
Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.
The following table presents a breakdown of such adjustments:
Three Months Ended
March 28,
March 29,
2026
2025
Adjustments:
Restructuring and related costs
$
(12)
$
(25)
Acquisition intangible amortization
(45)
(43)
Cyber incident-insurance proceeds, net of third-party advisory expenses
-
20
Change in contingent consideration
(1)
2
Impairment of intangible assets
-
(1)
Costs associated with shareholder advisory matters and select implementation related value
creation consulting costs
(13)
(8)
Total adjustments
$
(71)
$
(55)
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
14
Note 5
Business Acquisitions
Our acquisition strategy is focused on investments in companies, including
high growth high margin businesses
aligned with our BOLD+1 strategy, that add new customers and sales teams, increase our geographic footprint
(whether entering a new country, such as emerging markets, or building scale where we have already invested in
businesses), and finally, those that enable us to access new products and technologies.
2026 Acquisitions
During the three months ended March 28, 2026, we acquired companies
within the Global Distribution and Value-
Added Services and Global Specialty Products segments.
Our acquired ownership interest in these companies
range from
90
% to
100
%.
The following table aggregates the preliminary estimated fair value, as of
the date of the acquisition, of
consideration paid and net assets acquired for acquisitions during the three
months ended March 28, 2026:
Preliminary
Allocation as of
March 28, 2026
Acquisition consideration:
Cash
$
26
Deferred consideration
5
Common (or preferred) equity instruments
23
Fair value of previously held equity method investments
32
Redeemable noncontrolling interests
7
Total consideration
$
93
Identifiable assets acquired and liabilities assumed:
Current assets
$
13
Intangible assets
33
Other noncurrent assets
4
Current liabilities
(18)
Deferred income taxes
(6)
Other noncurrent liabilities
(1)
Total identifiable
net assets
25
Goodwill
68
Total net assets acquired
$
93
The accounting for acquisitions in the three months ended March 28, 2026
has not been completed in several areas,
including, but not limited to, pending assessment of certain assets,
primarily including identifiable intangibles, and
certain liabilities, primarily including deferred income taxes.
Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions
are expected to provide
for us, as well as the expected growth potential.
The majority of the acquired goodwill is not deductible
for tax
purposes.
The following table summarizes the intangible assets acquired during the
three months ended March 28, 2026:
Weighted Average
2026
Useful Lives (in years)
Customer relationships and lists
$
29
9
Trademarks / Tradenames
4
5
Total
$
33
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
15
During the three months ended March 28, 2026,
in connection with an acquisition of a controlling interest of an
affiliate, we recognized a gain of approximately $
11
million related to the remeasurement to fair value of our
previously held equity investment.
Such gain was calculated using a discounted cash flow model based on
Level 3
inputs, as defined in
,
which was recorded in
selling, general and administrative
in the condensed consolidated statements of income.
The impact of these acquisitions, individually and in the aggregate, was
not considered material to our condensed
consolidated financial statements.
Pro forma financial information since the acquisition date has not been presented
because the impact of these
acquisitions was immaterial to our condensed consolidated
financial statements.
2025 Acquisitions
During the year ended December 27, 2025, we acquired companies within
the Global Distribution and Value-
Added Services,
Global Specialty Products and Global Technology segments.
Our acquired ownership interest in
these companies range from
60
% to
100
%.
The following table aggregates the preliminary estimated fair value, as of
the date of the acquisition, of
consideration paid and net assets acquired for acquisitions during the year ended
December 27, 2025:
Preliminary
Allocation as of
March 28, 2026
Acquisition consideration:
Cash
$
194
Deferred consideration
3
Estimated fair value of contingent consideration payable
19
Fair value of previously held equity method investments
89
Redeemable noncontrolling interest
85
Total consideration
$
390
Identifiable assets acquired and liabilities assumed:
Current assets
$
61
Intangible assets
146
Other noncurrent assets
45
Current liabilities
(27)
Long-term debt
(2)
Deferred income taxes
(23)
Other noncurrent liabilities
(7)
Total identifiable
net assets
193
Goodwill
197
Total net assets acquired
$
390
The accounting for certain acquisitions in the year ended December 27,
2025 has not been completed in several
areas, including, but not limited to, pending assessment of certain
assets, primarily including identifiable
intangibles, and certain liabilities, primarily including deferred income
taxes.
Measurement period adjustments
recorded through March 28, 2026 were immaterial and primarily related to certain
intangible assets.
Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions
are expected to provide
for us, as well as the expected growth potential.
The majority of the acquired goodwill is not deductible
for tax
purposes.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
16
The following table summarizes the intangible assets acquired during the year
ended December 27, 2025:
Weighted Average
2025
Useful Lives (in years)
Customer relationships and lists
$
91
11
Trademarks / Tradenames
35
7
Product development
18
10
Non-compete agreements
2
5
Total
$
146
Pro forma financial information for our 2025 acquisitions has not been
presented because the impact of these
acquisitions was immaterial to our condensed consolidated
financial statements.
Acquisition Costs
During the three months ended March 28, 2026 and March 29, 2025, we incurred
$
2
million and $
2
million in
acquisition costs, respectively.
These costs are included in selling, general and administrative
in our condensed
consolidated statements of income.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
17
Note 6 – Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or
paid to transfer a liability in an orderly
transaction between market participants at the measurement date.
The fair value hierarchy distinguishes between
(1) market participant assumptions developed based on market data obtained
from independent sources (observable
inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best
information available in the circumstances (unobservable inputs).
The fair value hierarchy consists of three broad levels, which gives the
highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (Level 1) and the lowest priority
to unobservable inputs (Level 3).
The three levels of the fair value hierarchy are described as follows:
Level 1— Unadjusted quoted prices in active markets for identical assets
or liabilities that are accessible at the
measurement date.
Level 2— Inputs other than quoted prices included within Level 1 that are
observable for the asset or liability,
either directly or indirectly.
Level 2 inputs include: quoted prices for similar assets or liabilities
in active markets;
quoted prices for identical or similar assets or liabilities in markets
that are not active; inputs other than quoted
prices that are observable for the asset or liability; and inputs that are
derived principally from or corroborated by
observable market data by correlation or other means.
Level 3— Inputs that are unobservable for the asset or liability.
The following section describes the fair values of our financial instruments
and the methodologies that we used to
measure their fair values.
Investments and notes receivable
There are no quoted market prices available for investments in unconsolidated
affiliates and notes receivable.
Certain of our notes receivable contain variable interest rates.
We believe the carrying amounts of the notes
receivable are a reasonable estimate of fair value based on the interest rates
in the applicable markets.
Our notes
receivable fair value is based on Level 3 inputs within the fair value
hierarchy.
Debt
The fair value of our debt (including bank credit lines, current maturities
of long-term debt and long-term debt) is
based on Level 3 inputs within the fair value hierarchy, and as of March 28, 2026 and December 27, 2025 was
estimated at $
3,408
million and $
3,107
million, respectively.
Factors that we considered when estimating the fair
value of our debt include market conditions, such as interest rates and credit
spreads.
Derivative contracts
Derivative contracts are valued using quoted market prices and
significant other observable inputs.
Our derivative
instruments primarily include foreign currency forward contracts, interest
rate swaps and total return swaps.
The fair values for the majority of our foreign currency derivative contracts
are obtained by comparing our contract
rate to a published forward price of the underlying market rates, which
are based on market rates for comparable
transactions that are classified within Level 2 of the fair value hierarchy.
The fair value of the interest rate swap, which is classified within Level 2
of the fair value hierarchy, is determined
by comparing our contract rate to a forward market rate as of the
valuation date.
The fair value of total return swaps is determined by valuing the underlying
exchange traded funds of the swap
using market-on-close pricing by industry providers as of the valuation
date that are classified within Level 2 of the
fair value hierarchy.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
18
Redeemable noncontrolling interests
The values for redeemable noncontrolling interests are based on recent
transactions and/or implied multiples of
earnings that are classified within Level 3 of the fair value hierarchy.
See
for additional information.
Intangible Assets
Assets measured on a non-recurring basis at fair value include intangibles.
Inputs for measuring intangibles are
classified as Level 3 within the fair value hierarchy.
Defined Benefit Plans
Assets of our defined benefit plans are measured on a recurring basis
and are classified as Level 1 within the fair
value hierarchy.
Contingent Consideration
We estimate the fair value of contingent consideration payments as part of the acquisition price and record the
estimated fair value of contingent consideration as a liability on our
condensed consolidated balance sheets.
For
transactions accounted for as business combinations, subsequent changes
in the estimated fair value of contingent
consideration payments are included in selling, general and administrative
expenses in our condensed consolidated
statements of income
(see
.
For transactions involving changes in our ownership in
consolidated subsidiaries without a change in our control, subsequent
changes in the estimated fair value of
contingent consideration payments are recognized in additional paid-in
capital in our condensed consolidated
balance sheets.
We measure contingent consideration at the fair value on a recurring basis using significant
unobservable inputs classified as Level 3 of the fair value hierarchy.
We use various valuation techniques,
including the Monte Carlo simulation and probability-weighted scenarios,
to determine the fair value of the
contingent consideration liabilities on the acquisition date and at each
reporting period.
Our fair value
measurement inputs include expected operating performance, discount
and risk-free rates, and credit spread.
Contingent consideration is remeasured to fair value at each reporting
period.
During the three months ended
March 28, 2026,
we updated the fair value of contingent consideration
in connection with 2025 and 2023 business
acquisitions, which resulted in expense of $
2
million and income of $
1
million, respectively.
During the three
months ended March 29, 2025,
we updated the fair value of contingent consideration in connection
with a 2023
business acquisition, which resulted in income of $
2
million.
These changes were recorded in selling, general and
administrative in the condensed consolidated statements of income.
During the three months ended March 28,
2026 and March 29, 2025, we also updated the fair value of contingent
consideration related to changes in
ownership in our consolidated subsidiaries.
These changes were recorded within additional paid-in capital in
the
condensed consolidated balance sheets.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
19
The components of the change in the fair value of contingent consideration
for the three months ended March 28,
2026 and March 29, 2025 are presented in the following table:
Three Months Ended
March 28,
March 29,
2026
2025
Balance, beginning of period
$
97
$
30
Increase in contingent consideration due to business acquisitions and acquisitions of
noncontrolling interests in subsidiaries
-
93
Decrease in contingent consideration due to payments
-
(12)
Change in fair value of contingent consideration in connection with business acquisitions
1
(2)
Change in fair value of contingent consideration in connection with changes in ownership in
consolidated subsidiaries
(34)
3
Balance, end of period
$
64
$
112
The following table presents our assets and liabilities that are measured and
recognized at fair value on a recurring
basis classified under the appropriate level of the fair value hierarchy as of
March 28, 2026 and December 27,
2025:
March 28, 2026
Level 1
Level 2
Level 3
Total
Assets:
Derivative contracts designated as hedges
$
-
$
1
$
-
$
1
Derivative contracts undesignated
-
1
-
1
Total assets
$
-
$
2
$
-
$
2
Liabilities:
Derivative contracts designated as hedges
$
-
$
11
$
-
$
11
Derivative contracts undesignated
-
1
-
1
Total return
swap
-
9
-
9
Contingent consideration
-
-
64
64
Total liabilities
$
-
$
21
$
64
$
85
Redeemable noncontrolling interests
$
-
$
-
$
903
$
903
December 27, 2025
Level 1
Level 2
Level 3
Total
Assets:
Derivative contracts designated as hedges
$
-
$
1
$
-
$
1
Derivative contracts undesignated
-
1
-
1
Total return
swap
-
1
-
1
Total assets
$
-
$
3
$
-
$
3
Liabilities:
Derivative contracts designated as hedges
$
-
$
23
$
-
$
23
Derivative contracts undesignated
-
2
-
2
Contingent consideration
-
-
97
97
Total liabilities
$
-
$
25
$
97
$
122
Redeemable noncontrolling interests
$
-
$
-
$
895
$
895
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
20
Note 7 – Debt
Bank Credit Lines
Bank credit lines consisted of the following:
March 28,
December 27,
2026
2025
Revolving credit agreement
$
400
$
100
Other short-term bank credit lines
646
664
Total
$
1,046
$
764
Revolving Credit Agreement
On
August 20, 2021
, we entered into a $
1.0
billion revolving credit agreement (the “Revolving Credit Agreement”)
which was amended and restated on
July 11, 2023
to extend the maturity date to
July 11, 2028
and update the
interest rate provisions to reflect the current market approach for a
multicurrency facility.
On June 6, 2025, we
amended and restated the Revolving Credit Agreement to, among other
things, modify certain financial definitions
and covenants.
The interest rate on this revolving credit facility is based on Term Secured Overnight Financing
Rate (“
Term SOFR
”) plus a spread based on our leverage ratio at the end
of each financial reporting quarter.
As of
March 28, 2026 the interest rate on this revolving credit facility was
3.67
% plus
1.08
%, for a combined rate of
4.75
%.
As of December 27, 2025, the interest rate on this revolving credit
facility was
3.78
% plus
1.08
%, for a
combined rate of
4.86
%.
The Revolving Credit Agreement requires, among other things, that we
maintain certain maximum leverage ratios.
Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative
covenants as well as customary negative covenants, subject to negotiated
exceptions, on liens, indebtedness,
significant corporate changes (including mergers), dispositions and certain restrictive
agreements.
As of March 28,
2026 and December 27, 2025, we had $
400
million and $
100
million in borrowings, respectively, under this
revolving credit facility.
During the three months ended March 28, 2026, the average
outstanding balance under
the Revolving Credit Agreement was approximately $
327
million.
As of March 28, 2026 and December 27, 2025,
there were $
10
million and $
10
million of letters of credit, respectively, provided to third parties under the
Revolving Credit Agreement.
Other Short-Term Bank Credit
Lines
As of March 28, 2026 and December 27, 2025,
we had various other short-term bank credit lines available,
in
various currencies, with a maximum borrowing capacity of $
782
million and $
787
million, respectively.
As of
March 28, 2026 and December 27, 2025, $
646
million and $
664
million, respectively, were outstanding.
During
the three months ended March 28, 2026, the average outstanding balances
under our various other short-term bank
credit lines was approximately $
677
million.
As of March 28, 2026 and December 27, 2025, borrowings under
other short-term bank credit lines had weighted average interest rates
of
4.54
% and
4.68
%, respectively.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
21
Long-term debt
Long-term debt consisted of the following:
March 28,
December 27,
2026
2025
Private placement facilities
$
1,199
$
1,149
Term loan
749
749
U.S. trade accounts receivable securitization
360
390
Various
collateralized and uncollateralized loans payable with interest,
in varying installments through 2031 at interest rates
from
0.00
% to
6.25
% at March 28, 2026 and
from
0.00
% to
6.75
% at December 27, 2025
48
48
Finance lease obligations
6
7
Total
2,362
2,343
Less current maturities
(35)
(33)
Total long-term debt
$
2,327
$
2,310
Private Placement Facilities
Our private placement facilities provided by
four
insurance companies have a total facility amount of $
1.5
billion,
and are available on an uncommitted basis at fixed rate economic terms
to be agreed upon at the time of issuance,
from time to time through
December 19, 2028
.
The facilities allow us to issue senior promissory notes to the
lenders at a fixed rate based on an agreed upon spread over applicable treasury
notes at the time of issuance.
The
term of each possible issuance will be selected by us and can range from
five
to
15 years
(with an average life no
longer than
12 years
).
The proceeds of any issuances under the facilities will be used for
general corporate
purposes, including working capital and capital expenditures, to refinance
existing indebtedness, and/or to fund
potential acquisitions.
On December 19, 2025, we amended and restated our private placement
facilities to, among
other things, (i) extend the scheduled facility termination dates to December
19, 2028 and (ii) modify certain
financial definitions and covenants.
The agreements provide, among other things, that we
maintain certain
maximum leverage ratios, and contain restrictions relating to subsidiary
indebtedness, liens, affiliate transactions,
disposal of assets and certain changes in ownership.
These facilities contain make-whole provisions in the event
that we pay off the facilities prior to the applicable due dates.
The components of our private placement facility borrowings as of
March 28, 2026, which have a weighted average
interest rate of
3.99
%, are presented in the following table:
Amount of
Date of
Borrowing
Borrowing
Borrowing
Outstanding
Rate
Due Date
June 16, 2017
$
100
3.42
%
June 16, 2027
September 15, 2017
100
3.52
September 15, 2029
January 2, 2018
100
3.32
January 2, 2028
September 2, 2020
100
2.35
September 2, 2030
June 2, 2021
100
2.48
June 2, 2031
June 2, 2021
100
2.58
June 2, 2033
May 4, 2023
75
4.79
May 4, 2028
May 4, 2023
75
4.84
May 4, 2030
May 4, 2023
75
4.96
May 4, 2033
May 4, 2023
150
4.94
May 4, 2033
December 15, 2025
100
5.23
December 15, 2032
December 15, 2025
75
5.28
December 15, 2032
February 24, 2026
50
5.40
February 24, 2034
Less: Deferred debt issuance costs
(1)
Total
$
1,199
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
22
The components of our private placement facility borrowings as of December
27, 2025, which have a weighted
average interest rate of
3.93
%, are presented in the following table:
Amount of
Date of
Borrowing
Borrowing
Borrowing
Outstanding
Rate
Due Date
June 16, 2017
$
100
3.42
%
June 16, 2027
September 15, 2017
100
3.52
September 15, 2029
January 2, 2018
100
3.32
January 2, 2028
September 2, 2020
100
2.35
September 2, 2030
June 2, 2021
100
2.48
June 2, 2031
June 2, 2021
100
2.58
June 2, 2033
May 4, 2023
75
4.79
May 4, 2028
May 4, 2023
75
4.84
May 4, 2030
May 4, 2023
75
4.96
May 4, 2033
May 4, 2023
150
4.94
May 4, 2033
December 15, 2025
100
5.23
December 15, 2032
December 15, 2025
75
5.28
December 15, 2032
Less: Deferred debt issuance costs
(1)
Total
$
1,149
Term Loan
On July 11, 2023, we entered into a
three-year
$
750
million term loan credit agreement (the “Term Credit
Agreement”), which was originally scheduled to mature on
July 11, 2026
.
On June 6, 2025, this agreement was
amended and restated to, among other things, (i) extend the maturity date
to
June 6, 2030
, and (ii) modify certain
financial definitions and covenants.
The interest rate on this term loan is based on the
Term SOFR
plus a spread
based on our leverage ratio at the end of each financial reporting quarter.
Beginning in June 2026 and continuing
through June 2027, we are required to make quarterly payments of $
5
million.
In September 2027, the quarterly
payment amount increases to $
9
million, continuing through June 2030 with the remaining balance due June
6,
2030.
As of March 28, 2026, the borrowings outstanding under this
term loan were $
749
million.
At March 28,
2026, the interest rate under the Term Credit Agreement was
3.67
% plus
1.25
%, for a combined rate of
4.92
%.
As
of December 27, 2025, the borrowings outstanding under this term
loan were $
749
million.
At December 27, 2025,
the interest rate under the Term Credit Agreement was
3.76
% plus
1.25
%, for a combined rate of
5.01
%.
After
renewing the Term Credit Agreement in June of 2025, our hedged portion of the Term Credit Agreement is now
approximately
89
% of the notional total.
As of March 28, 2026, the effective fixed rate was
5.69
% and the floating
rate was
4.92
%, resulting in a weighted average rate of
5.60
%.
As of December 27, 2025, the effective fixed rate
was
5.69
% and the floating rate was
5.01
%, resulting in a weighted average rate of
5.62
%.
The Term Credit
Agreement requires, among other things, that we maintain certain maximum
leverage ratios.
Additionally, the
Term Credit Agreement contains customary representations, warranties and affirmative covenants as well as
customary negative covenants, subject to negotiated exceptions, on
liens, indebtedness, significant corporate
changes (including mergers), dispositions and certain restrictive agreements.
U.S. Trade Accounts Receivable Securitization
We have a facility agreement based on our U.S. trade accounts receivable that is structured as an asset-backed
securitization program with pricing committed for up to
three years
.
On December 6, 2024, we extended the
expiration date of this facility agreement to
December 6, 2027
.
This facility agreement has a purchase limit of $
450
million with
two
banks as agents.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
23
As of March 28, 2026 and December 27, 2025, the borrowings outstanding
under this securitization facility were
$
360
million and $
390
million, respectively.
At March 28, 2026, the interest rate on borrowings under
this facility
was based on the
asset-backed commercial paper rate
of
3.88
% plus
0.75
%, for a combined rate of
4.63
%.
At
December 27, 2025, the interest rate on borrowings under this facility was
based on the asset-backed commercial
paper rate of
4.06
% plus
0.75
%, for a combined rate of
4.81
%.
If our accounts receivable collection pattern changes due to customers
either paying late or not making payments,
our ability to borrow under this facility may be reduced.
We are required to pay a commitment fee of
30
to
35
basis
points depending upon program utilization.
Note 8 – Income Taxes
For the three months ended March 28, 2026, our effective tax rate was
25.5
%, compared to
24.9
% for the prior year
period.
The difference between our effective and federal statutory tax rates primarily relates to state and
foreign
income taxes and interest expense.
The total amount of unrecognized tax benefits, which are included in
“other liabilities” within our condensed
consolidated balance sheets, as of March 28, 2026 and December 27, 2025
was $
111
million and $
112
million,
respectively, of which $
103
million and $
104
million, respectively, would affect the effective tax rate if recognized.
All tax returns audited by the IRS are officially closed through 2021.
The tax years subject to examination by the
IRS include years 2022 and forward.
In addition, limited positions reported in the 2017 tax year are subject
to IRS
examination.
The amount of tax interest expense included as a component of the provision
for taxes was $
0
million and $
1
million during the three months ended March 28, 2026 and March
29, 2025,
respectively.
The total amount of
accrued interest is included in other liabilities within our condensed
consolidated balance sheets, and was $
22
million as of March 28, 2026 and December 27, 2025.
The amount of penalties accrued for during the periods
presented was not material to our condensed consolidated financial statements.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
24
Note 9 – Plan of Restructuring and Related Costs
On August 6, 2024, we committed to a restructuring plan (the “2024
Plan”) to integrate our acquisitions, right-size
operations and further increase efficiencies.
We currently expect this plan to be completed by the end of 2027.
During the three months ended March 28, 2026 and March 29, 2025, we recorded
restructuring and related charges
associated with the 2024 Plan of $
12
million and $
25
million, respectively.
The restructuring and related costs for
these periods primarily related to severance and employee-related costs,
costs to exit facilities and other exit costs.
We expect to record restructuring and related charges associated with the 2024 Plan through the end of 2027;
however, an estimate of the amount of these charges for 2026 through 2027 has not yet been determined.
During the quarter ended March 28, 2026, in connection with the
2024 Plan, we recorded a loss of $
2
million
related to the disposal of businesses in the Global Specialty Products segment.
This amount is included in the $
12
million of restructuring and related charges discussed above.
Restructuring and related costs recorded for the three months ended
March 28, 2026 and March 29, 2025 in
connection with the 2024
Plan consisted of the following:
Three Months Ended March 28, 2026
Global Distribution
and Value-Added
Services
Global
Specialty
Products
Global
Technology
Corporate
Total
Severance and employee-related costs
$
4
$
1
$
2
$
-
$
7
Impairment and accelerated depreciation and amortization
of right-of-use lease assets and other long-lived assets
-
1
-
-
1
Exit and other related costs
1
1
-
-
2
Loss on disposal of a business
-
2
-
-
2
Restructuring and related costs
$
5
$
5
$
2
$
-
$
12
Three Months Ended March 29, 2025
Global Distribution
and Value-Added
Services
Global
Specialty
Products
Global
Technology
Corporate
Total
Severance and employee-related costs
$
10
$
5
$
1
$
6
$
22
Impairment and accelerated depreciation and amortization
of right-of-use lease assets and other long-lived assets
1
-
-
-
1
Exit and other related costs
1
-
1
-
2
Restructuring and related costs
$
12
$
5
$
2
$
6
$
25
The following table summarizes the activity related to the liabilities associated
with our restructuring initiatives
for
the three months ended March 28, 2026.
The remaining accrued balance of restructuring and related costs
as of
March 28, 2026, which primarily relates to severance and employee-related costs,
is included in accrued expenses:
other within our condensed consolidated balance sheets.
Liabilities related to exited leased facilities are recorded
within our current and non-current operating lease liabilities within our condensed
consolidated balance sheets.
Total
Balance, December 27, 2025
$
49
Restructuring and related costs
12
Non-cash impairment, accelerated depreciation and amortization
(1)
Non-cash impairment on disposal of a business
(1)
Cash payments and other adjustments
(25)
Balance, March 28, 2026
$
34
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
25
Note 10 – Legal Proceedings
Henry Schein, Inc. was named as a defendant in multiple opioid related
lawsuits (one or more of Henry Schein,
Inc.’s subsidiaries was also named as a defendant in a number of those cases).
Generally, the lawsuits allege that
the manufacturers of prescription opioid drugs engaged in a false
advertising campaign to expand the market for
such drugs and their own market share and that the entities in the supply
chain (including Henry Schein, Inc. and its
subsidiaries) reaped financial rewards by refusing or otherwise failing to
monitor appropriately and restrict the
improper distribution of those drugs.
The last remaining actions which were consolidated within
the MultiDistrict
Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation
(MDL No. 2804; Case No. 17-md-
2804) have been settled for immaterial amounts and have been dismissed.
From time to time, we may become a party to other legal proceedings,
including, without limitation, product
liability claims, employment matters, commercial disputes, governmental
inquiries and investigations (which may
in some cases involve our entering into settlement arrangements or consent
decrees), and other matters arising out
of the ordinary course of our business.
While the results of any legal proceeding cannot be predicted with certainty,
in our opinion none of these other pending matters are currently
anticipated to have a material adverse effect on our
consolidated financial position, liquidity or results of operations.
As of March 28, 2026,
we had accrued our best estimate of potential losses relating
to claims that were probable to
result in liability and for which we were able to reasonably estimate a
loss.
This accrued amount, as well as related
expenses, was not material to our financial position, results of operations
or cash flows.
Our method for
determining estimated losses considers currently available
facts, presently enacted laws and regulations and other
factors, including probable recoveries from third parties.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
26
Note 11 – Stock-Based Compensation
Plan Administration and Award Types
Stock-based awards are granted to certain employees under the 2024 Stock
Incentive Plan and to our non-employee
directors under the 2023 Non-Employee Director Stock Incentive Plan (collectively, the “Plans”), which are
administered by the Compensation Committee of the Board of Directors.
Non-Employee Directors:
Receive awards exclusively in the form of time-based restricted stock units
(“RSUs”) with
12
-month cliff vesting.
An RSU entitles the holder to receive
one
share of Company
common stock upon vesting.
Employees:
Historically, awards were granted in varying forms, including RSUs, performance-based
restricted stock units (“PSUs”) and non-qualified stock options.
Beginning in the 2023 plan year, employee
awards consist of:
o
RSUs:
Vest
based on the recipient’s continued service over time.
o
PSUs:
A PSU entitles the holder to receive
one
share of Company common stock upon vesting,
contingent on the achievement of specified performance targets and the recipient’s continued
service.
The number of shares that ultimately vest and are received by
the recipient may range
above or below the target award based on the Company’s performance against pre-determined
specified targets over the applicable performance period, as determined by the Compensation
Committee.
o
Non-Qualified Stock Options (granted solely to our CEO in 2026):
Non-qualified stock options
(“Stock Options”) are awards that allow the recipient to purchase
shares of our common stock after
vesting at a fixed price set at the time of grant.
Stock Options are issued at an exercise price equal
to our closing stock price on the date of grant and have a contractual
term of
ten years
from the
grant date, subject to earlier expiration upon certain termination events and
accelerated vesting
upon certain events.
Allocation and Vesting Schedules
The following table summarizes
the allocation and vesting structure for our annual long-term incentive
(“LTI”)
equity awards to employee groups during the 2025 and 2026 plan years,
and for our CEO’s 2026 sign-on equity
award:
Employee Group
Plan Year
Award Allocation
Vesting Structure
CEO
2026
25
%
RSU (time)
4
-year graded
(
25
%/year)
25
%
PSU (performance)
3
-year cliff
50
%
Stock Options
4
-year graded
(
25
%/year)
2026 (Sign-On)
100
%
RSU (time)
3
-year graded
(
33
-1/3%/year)
2025
35
%
RSU (time)
4
-year cliff
65
%
PSU (performance)
3
-year cliff
Executive Management Committee
2026
50
%
RSU (time)
4
-year graded
(
25
%/year)
50
%
PSU (performance)
3
-year cliff
2025
50
%
RSU (time)
4
-year cliff
50
%
PSU (performance)
3
-year cliff
Vice Presidents
2026
80
%
RSU (time)
4
-year graded
(
25
%/year)
20
%
PSU (performance)
3
-year cliff
2025
80
%
RSU (time)
50
% at 3rd year /
50
% at 4th year
20
%
PSU (performance)
3
-year cliff
Director Level
2026
100
%
RSU (time)
4
-year graded
(
25
%/year)
2025
100
%
RSU (time)
50
% at 3rd year /
50
% at 4th year
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
27
Accounting Policy Change
Effective in the first quarter of 2026, we updated our accounting policy for recognizing
stock-based compensation
expense for awards with service conditions only, transitioning from the graded-vesting method to the straight-line
method.
We adopted this change as we believe the straight-line method is the predominant practice in our industry.
The effect of this change in accounting policy and its impact on our consolidated
financial statements was
immaterial for retrospective application.
Valuation
and Performance Measurements
RSUs and PSUs: For RSUs and PSUs, fair value is estimated based on the
closing stock price on the grant
date.
For PSUs, the number of shares that ultimately vest and are received by
the recipient and related
compensation cost recognized as an expense may range above or below
the target based on the Company’s
performance against pre-determined specified targets over the applicable performance
period, as
determined by the Compensation Committee.
Stock Options: Compensation expense is recognized on a straight-line
basis, and grant-date fair value is
estimated using the Black-Scholes valuation model.
Performance Adjustments
The equity awards under the Plans are subject to certain pre-determined
adjustments to the performance
measurements to the extent that related activities were not contemplated
in the original goals.
With respect to PSUs
granted under the 2024 Stock Incentive Plan, for the 2025, and 2026 PSUs,
these adjustments may include, but are
not limited to:
Impact of acquisitions, divestitures, and new business ventures.
Changes in the fair value of contingent consideration and remeasurement
gains related to acquisitions.
Certain capital transactions, including share repurchases.
Impact of differences in budgeted average outstanding shares (other than those resulting
from capital
transactions referred to above).
Restructuring and related costs.
Amortization expense recorded for acquisition-related intangible assets.
Certain litigation settlements or payments.
Changes in accounting principles or in applicable laws or regulations.
Changes in income tax rates in certain markets.
Foreign exchange fluctuations.
Intangible impairment charges.
Costs related to shareholder advisory matters (for 2025 and 2026 PSU
grants only).
Implementation-related value creation consulting costs (for 2026 PSU
grants only).
Our condensed consolidated statements of income reflect pre-tax share-based compensation
expense of $
3
million
and $
5
million for the three months ended March 28, 2026 and March 29, 2025, respectively.
Total unrecognized compensation cost related to unvested awards as of March 28, 2026 was $
119
million, which is
expected to be recognized over a weighted-average period of approximately
3.0
years.
Our condensed consolidated statements of cash flows present our
stock-based compensation expense as a
reconciling adjustment between net income and net cash provided by operating
activities for all periods presented.
There were no cash benefits associated with tax deductions in excess of
recognized compensation for the three
months ended March 28, 2026 and March 29, 2025.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
28
The following weighted-average assumptions were used in determining
the most recent fair values of stock options
using the Black-Scholes valuation model:
2026
Expected dividend yield
0.0
%
Expected stock price volatility
29.00
%
Risk-free interest rate
3.82
%
Expected life of options (years)
6.00
We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in
the foreseeable future.
The expected stock price volatility is based on implied volatilities
from traded options on
our stock, historical volatility of our stock and other factors.
The risk-free interest rate is based on the U.S.
Treasury yield curve in effect at the time of grant that most closely aligns to the expected life of options.
The
six
-
year expected life of the options was determined using the simplified
method for estimating the expected term as
permitted under Staff Accounting Bulletin Topic 14.
The following table summarizes the stock option activity for the three
months ended March 28, 2026:
Stock Options
Weighted Average
Aggregate
Weighted Average
Remaining Contractual
Intrinsic
Shares
Exercise Price
Life (in years)
Value
Outstanding at beginning of period
922,715
$
72.26
Granted
177,116
77.60
Exercised
(16,420)
64.17
Forfeited
(1,350)
85.51
Outstanding at end of period
1,082,061
$
73.24
6.1
$
5
Options exercisable at end of period
904,945
$
72.38
The following tables summarize the activity of our unvested RSUs and PSUs for
the three months ended March 28,
2026:
RSUs (Time-Based)
PSUs (Performance-Based)
Weighted Average
Weighted Average
Grant Date Fair
Grant Date Fair
Shares/Units
Value Per Share
Shares/Units
Value Per Share
Outstanding at beginning of period
1,606,542
$
75.69
387,960
$
75.89
Granted
646,793
77.78
227,501
74.25
Performance adjustment
n/a
n/a
300,049
74.97
Vested
(302,090)
84.05
(80,950)
81.54
Forfeited
(43,957)
76.07
(295,611)
77.00
Outstanding at end of period
1,907,288
$
75.06
538,949
$
74.88
The fair value of vested RSUs and PSUs was $
25
million and $
7
million, respectively, for the three months ended
March 28, 2026; and $
33
million and $
1
million, respectively, for the three months ended March 29, 2025.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
29
Note 12 – Redeemable Noncontrolling Interests
Some minority stockholders in certain of our subsidiaries have the right,
at certain times, to require us to acquire
their ownership interest in those entities at fair value.
Accounting Standards Codification Topic 480-10 is
applicable for noncontrolling interests where we are or may be required
to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling
interest holder under the terms of a put
option contained in contractual agreements.
The components of the change in the redeemable noncontrolling
interests for the three months ended March 28, 2026 and March 29, 2025
are presented in the following table:
March 28,
March 29,
2026
2025
Balance, beginning of period
$
895
$
806
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling
interests in subsidiaries
(32)
(73)
Increase in redeemable noncontrolling interests due to business acquisitions
29
-
Net loss attributable to redeemable noncontrolling interests
(1)
(2)
Distributions declared
(9)
(2)
Effect of foreign currency translation gain attributable to redeemable noncontrolling
interests
3
8
Change in fair value of redeemable securities
18
28
Balance, end of period
$
903
$
765
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
30
Note 13 – Comprehensive Income
Comprehensive income includes certain gains and losses that, under U.S.
GAAP,
are excluded from net income and
are recorded directly to stockholders’ equity.
The following table summarizes our Accumulated other comprehensive loss, net of
applicable taxes as of:
March 28,
December 27,
2026
2025
Attributable to redeemable noncontrolling interests:
Foreign currency translation adjustment
$
(23)
$
(26)
Attributable to noncontrolling interests:
Foreign currency translation adjustment
$
1
$
1
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment
$
(167)
$
(196)
Unrealized loss from hedging activities
(16)
(24)
Pension adjustment loss
(6)
(6)
Accumulated other comprehensive loss
$
(189)
$
(226)
Total Accumulated
other comprehensive loss
$
(211)
$
(251)
The following table summarizes the components of comprehensive income, net
of applicable taxes as follows:
Three Months Ended
March 28,
March 29,
2026
2025
Net income
$
112
$
113
Foreign currency translation gain
32
76
Tax effect
-
-
Foreign currency translation gain
32
76
Unrealized gain (loss) from hedging activities
11
(6)
Tax effect
(3)
1
Unrealized gain (loss) from hedging activities
8
(5)
Pension adjustment gain
-
1
Tax effect
-
(1)
Pension adjustment gain
-
-
Comprehensive income
$
152
$
184
Our financial statements are denominated in U.S. Dollars.
Fluctuations in the value of foreign currencies as
compared to the U.S. Dollar may have a significant impact on our
comprehensive income.
The foreign currency
translation gain (loss) during the three months ended March 28, 2026 and
three months ended March 29, 2025 was
primarily due to changes in foreign currency exchange rates of the Brazilian
Real, Euro, British Pound, and Israel
Shekel.
The hedging gain (loss) during the three months ended March 28, 2026 and
March 29, 2025 was attributable to a
net investment hedge.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
31
The following table summarizes our total comprehensive income, net of
applicable taxes as follows:
Three Months Ended
March 28,
March 29,
2026
2025
Comprehensive income attributable to
Henry Schein, Inc.
$
144
$
172
Comprehensive income attributable to
noncontrolling interests
6
6
Comprehensive income attributable to
Redeemable noncontrolling interests
2
6
Comprehensive income
$
152
$
184
Note 14
Earnings Per Share
Basic earnings per share is computed by dividing net income attributable
to Henry Schein, Inc. by the weighted-
average number of common shares outstanding for the period.
Our diluted earnings per share is computed similarly
to basic earnings per share, except that it reflects the effect of common shares issuable
for unvested RSUs and upon
exercise of stock options using the treasury stock method in periods
in which they have a dilutive effect.
A reconciliation of shares used in calculating earnings per basic and
diluted share follows:
Three Months Ended
March 28,
March 29,
2026
2025
Basic
114,939,640
123,776,073
Effect of dilutive securities:
Stock options and restricted stock units
1,121,604
1,072,148
Diluted
116,061,244
124,848,221
The number of antidilutive securities that were excluded from the calculation
of diluted weighted average common
shares outstanding are as follows:
Three Months Ended
March 28,
March 29,
2026
2025
Stock options
403,885
402,268
Restricted stock units
10,315
200,568
Total anti-dilutive
securities excluded from earnings per share computation
414,200
602,836
Note 15 – Supplemental Cash Flow Information
Cash paid for interest and income taxes was:
Three Months Ended
March 28,
March 29,
2026
2025
Cash paid for interest
$
33
$
32
Cash paid for income taxes, net of refunds
24
18
For the three months ended March 28, 2026 and March 29, 2025, we
had $
11
million and $
(6)
million of non-cash
net unrealized gains (losses) related to hedging activities, respectively.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
32
Note 16 – Related Party Transactions
During 2018, we entered into a joint venture with Internet Brands to create Henry
Schein One, LLC.
Internet
Brands initially held a
26
% noncontrolling interest, which has since increased to a
33.6
% noncontrolling interest in
Henry Schein One, LLC, and a freestanding and separately exercisable right
to put its noncontrolling interest to
Henry Schein, Inc. for fair value following the fifth anniversary of the effective date of the
formation of the joint
venture.
On January 29, 2025, Henry Schein, Inc. signed a Memorandum of Understanding
with Internet Brands to
extend the time-based trigger for the exercise of our call option to July 1, 2032
and to pause the exercise by Internet
Brands of its put option for a period of
four years
, to January 29, 2029.
In connection with the formation of Henry Schein One, LLC we entered
into a
ten-year
royalty agreement with
Internet Brands whereby we will pay Internet Brands approximately $
31
million annually for the use of their
intellectual property.
During the three months ended March 28, 2026 and March
29, 2025, we recorded $
8
million
and $
8
million, respectively, within selling, general and administrative in our condensed consolidated statements of
income, in connection with costs related to this royalty agreement.
As of March 28, 2026 and December 27, 2025,
Henry Schein One, LLC had a net payable balance to Internet Brands of $
8
million and $
9
million, respectively,
comprised of amounts related to results of operations and the royalty agreement.
The components of this payable
are recorded within accrued expenses: other within our condensed consolidated balance
sheets.
We have interests in entities that we account for under the equity accounting method.
In our normal course of
business, during the three months ended March 28, 2026 and March 29,
2025, we recorded net sales of $
7
million
and $
13
million respectively, to such entities.
During the three months ended March 28, 2026 and March 29,
2025,
we purchased $
2
million and $
2
million respectively, from such entities.
At March 28, 2026 and December 27,
2025, we had an aggregate $
31
million and $
39
million, respectively, due from our equity affiliates, and $
3
million
and $
7
million, respectively, due to our equity affiliates.
Certain of our facilities related to our acquisitions are leased from employees
and minority shareholders.
These
leases are classified as operating leases and have a remaining lease term ranging
from less than
a
year to
approximately
11 years
.
As of March 28, 2026, current and non-current liabilities associated with
related party
operating leases were $
5
million and $
21
million, respectively.
At March 28, 2026, related party leases represented
7.0
% and
7.9
% of the total current and non-current operating lease liabilities, respectively.
At December 27, 2025,
current and non-current liabilities associated with related party operating
leases were $
5
million and $
22
million,
respectively.
At December 27, 2025, related party leases represented
6.6
% and
8.7
% of the total current and non-
current operating lease liabilities, respectively.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
33
Note 17 – KKR Investment and Accelerated Share Repurchase Program
On January 29, 2025, Henry Schein, Inc. announced a strategic investment
by investment funds and other entities
affiliated with Kohlberg Kravis Roberts & Co. L.P. (“KKR”),
pursuant to the terms of a Strategic Partnership
Agreement with KKR (the “Agreement”).
Under the Agreement,
two
independent directors, Max Lin and William
K. “Dan” Daniel (each, and any replacement thereof, a “KKR Designee”),
joined our Board of Directors.
On May
16, 2025, we issued
3,285,152
shares of common stock to funds affiliated with KKR for an investment of $
250
million, at approximately $
76.10
per share.
On May 19, 2025, we executed an accelerated share repurchase program
to repurchase a total of $
250
million of
our outstanding common stock based on volume-weighted average prices.
In May 2025 we received
3,122,832
shares at an estimated fair value of $
224
million.
In July 2025, we received an additional
368,651
shares at an
estimated fair value of $
26
million, representing the final amount of shares to be received under
this accelerated
share repurchase program.
Pursuant to the Agreement, KKR also had the ability to purchase additional
shares via open market purchases up to
a total equity stake of
14.9
% of the outstanding shares of common stock of the Company.
On November 4, 2025,
the Company and KKR entered into an amendment to the Agreement
that increased the beneficial ownership limit
from
14.9
% to
19.9
% of the outstanding shares of the Company’s common stock that KKR is permitted to acquire
during the standstill period.
The standstill provisions, including the increased ownership limit, continue
in effect
for a period of six months following the later of the expiration of the term of
the Agreement and the date on which
no director appointed pursuant to the Agreement is serving on the Board
of Directors.
On December 7, 2025,
pursuant to the Agreement, KKR notified the Company of its election
to exercise the Extension Election (as defined
in the Agreement) whereby the Company’s Board of Directors has accordingly renominated the KKR Designees
to
stand for election at the Company’s upcoming 2026 annual meeting of stockholders for a term expiring at
the
Company’s 2027 annual meeting of stockholders.
34
ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities
Litigation Reform Act of 1995, we
provide the following cautionary remarks regarding important factors
that, among others, could cause future results
to differ materially from the forward-looking statements, expectations and assumptions
expressed or implied herein.
All forward-looking statements made by us are subject to risks and uncertainties
and are not guarantees of future
performance.
These forward-looking statements involve known and unknown
risks, uncertainties and other factors
that may cause our actual results, performance and achievements
or industry results to be materially different from
any future results, performance or achievements expressed or implied
by such forward-looking statements.
These
statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,”
“plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to
make” or other comparable terms.
Factors that
could cause or contribute to such differences include, but are not limited to,
those discussed in the documents we
file with the Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K.
Risk factors and uncertainties that could cause actual results to differ materially from
current and historical results
include, but are not limited to: our dependence on third parties for
the manufacture and supply of our products and
where we manufacture products, our dependence on third parties
for raw materials or purchased components; risks
relating to the achievement of our strategic growth objectives, including
anticipated results of restructuring and
value creation initiatives; risks related to the Strategic Partnership Agreement
with KKR Hawaii Aggregator L.P.
entered into in January 2025; transitions in senior company leadership
(including, without limitation, the transition
to our new Chief Executive Officer); our ability to develop or acquire and
maintain and protect new products
(particularly technology and specialty products) and services and utilize
new technologies that achieve market
acceptance with acceptable margins; transitional challenges associated with acquisitions
and joint ventures,
including the failure to achieve anticipated synergies/benefits, as well as significant
demands on our operations,
information systems, legal, regulatory, compliance, financial and human resources functions in connection with
acquisitions, dispositions and joint ventures; certain provisions
in our governing documents that may discourage
third-party acquisitions of us; adverse changes in supplier rebates
or other purchasing incentives; risks related to the
sale of corporate brand products; risks related to activist investors; security
risks associated with our information
systems and technology products and services, such as cyberattacks or
other privacy or data security breaches
(including the October 2023 incident); effects of a highly competitive (including,
without limitation, competition
from third-party online commerce sites) and consolidating market; political,
economic and regulatory influences on
the health care industry; risks from expansion of customer purchasing
power and multi-tiered costing structures;
increases in shipping costs for our products or other service issues
with our third-party shippers, and increases in
fuel and energy costs; changes in laws and policies governing manufacturing, development
and investment in
territories and countries where we do business; general global and domestic
macro-economic and political
conditions, including inflation, deflation, recession, unemployment (and corresponding
increase in under-insured
populations), consumer confidence, sovereign debt levels, fluctuations in
energy pricing and the value of the U.S.
dollar as compared to foreign currencies and changes to other economic
indicators; failure to comply with existing
and future regulatory requirements, including relating to health care;
risks associated with the EU Medical Device
Regulation; failure to comply with laws and regulations relating to health
care fraud or other laws and regulations;
failure to comply with laws and regulations relating to the collection, storage
and processing of sensitive personal
information or standards in electronic health records or transmissions;
changes in tax legislation, changes in tax
rates and availability of certain tax deductions; risks related to product
liability, intellectual property and other
claims; risks associated with customs policies or legislative import restrictions;
risks associated with disease
outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or
similar wide-spread public health concerns
and other natural or man-made disasters; risks associated with our global
operations; the threat or outbreak of war
(including, without limitation, geopolitical wars), terrorism or public unrest
(including, without limitation, the wars
in Ukraine and Iran, the Israel-Gaza war and other unrest and threats in the Middle
East and the possibility of a
wider European or global conflict); changes to laws and policies governing
foreign trade, tariffs and sanctions or
greater restrictions on imports and exports, including changes to international
trade agreements and the current
imposition of (and the potential for additional) tariffs by the U.S. on numerous
countries and retaliatory tariffs;
supply chain disruption; litigation risks; new or unanticipated litigation
developments and the status of litigation
matters; our dependence on our senior management, employee hiring and
retention, increases in labor costs or
35
health care costs, and our relationships with customers, suppliers and
manufacturers; and disruptions in financial
markets.
The order in which these factors appear should not be construed
to indicate their relative importance or
priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control
or predict.
Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction
of actual results.
We undertake no duty and have no obligation to update forward-looking statements except as
required by law.
Where You
Can Find Important Information
We may disclose important information through one or more of the following channels: SEC filings, public
conference calls and webcasts, press releases, the investor relations
page of our website (www.henryschein.com)
and the social media channels identified on the About Media Center page
of our website.
Recent Developments
Chief Executive Officer
On January 12, 2026, we announced the appointment of Frederick
M. Lowery as CEO, effective March 2, 2026.
In
connection with his appointment, Mr. Lowery joined our Board of Directors.
Mr. Lowery succeeded Stanley M.
Bergman, who served as CEO through March 1, 2026.
Mr. Bergman retired as CEO and continues to serve as
Chairman of the Board.
Mr. Bergman will retire as Chairman of the Board as of the end of the 2026 Annual
Meeting of Stockholders and the Board has approved the appointment
of Mr. Bergman as Chairman Emeritus
effective upon his retirement as Chairman.
The Board intends to appoint a new Chairman promptly
following the
Company’s 2026 annual meeting of stockholders.
Tariffs and Related Economic Conditions
The U.S. has adopted new and increased tariffs on imports from countries, which
tariffs remain subject to
frequently evolving exemptions and modifications, as well as to court
challenges, including a recent invalidation in
the Supreme Court of many of the tariffs.
Some countries have imposed retaliatory tariffs and other restrictions on
imports from the U.S.
These developments, and anticipated future developments,
have created a volatile
environment for global trade, and new trade policies with individual countries.
It is unclear whether, or the extent
to which, the current tariffs on trade with numerous countries will remain in place,
or change, the exceptions that
may apply, and their timing.
The tariffs did not have a material impact on our results of operations during fiscal
year 2025, although sales of
U.S. dental equipment were temporarily impacted by market uncertainty
related to tariffs in the second half of the
quarter ended June 28, 2025.
36
Executive-Level Overview
Henry Schein, Inc. is a solutions company for health care professionals powered
by a network of people and
technology.
We
believe we are the world’s largest provider of health care products and services primarily to office-
based dental and medical practitioners, as well as alternate sites of care.
We
serve more than one million customers
worldwide including dental practitioners, laboratories, physician practices and
ambulatory surgery centers, as well
as government, institutional health care clinics, home health providers, and
other alternate care clinics.
We
believe
that we have a strong brand identity due to our more than 94 years of experience
distributing health care products.
We
are headquartered in Melville, New York, employ more than 25,000 people (of which more than 13,000 are
based outside of the United States) and have operations or affiliates in 34 countries and
territories.
Our broad
global footprint has evolved over time through our organic growth as well as through
contribution from strategic
acquisitions.
We
have established strategically located distribution centers around
the world to enable us to better serve our
customers and increase our operating efficiency.
This infrastructure, together with broad product and service
offerings at competitive prices, and a strong commitment to customer service, enables
us to be a single source of
supply for our customers’ needs.
As a distributor, we market and sell branded products as well as our own corporate brand portfolio of
cost-effective,
high-quality consumable merchandise products.
We
also manufacture, source and sell a range of company-owned
manufactured products, primarily implants, biomaterial products, endodontics, handpiece
and small equipment,
hand instrument and repair, restoratives, orthodontics, wound care, orthopedics and dental lab products.
We
have
achieved scale in these global businesses primarily through acquisitions, as
manufacturers of these products
typically do not utilize a distribution channel to serve customers.
Our reportable segments consist of: (i) Global Distribution and Value-Added Services; (ii) Global Specialty
Products; and (iii) Global Technology.
Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of
national brand and corporate brand merchandise, as well as equipment and related
technical services.
This segment
also includes value-added services such as financial services, continuing education
services, consulting and other
services.
This segment also markets and sells under our own corporate brand,
a portfolio of cost-effective, high-
quality consumable merchandise.
Global Specialty Products includes manufacturing, marketing
and sales of dental
implant and biomaterial products; and endodontic, orthodontic and orthopedic
products and other health care-
related products and services.
Global Technology includes development and distribution of practice management
software, e-services and other products, which are distributed to health
care providers.
A key element to grow closer to our customers is our One Schein initiative, which
is a unified go-to-market
approach that enables practitioners to work synergistically with our supply chain, equipment
sales and service and
other value-added services, allowing our customers to leverage the
combined value that we offer through a single
program.
Specifically, One Schein provides customers with streamlined access to our comprehensive offering of
national brand products, corporate brand products and proprietary specialty products
and solutions (including
implant, orthodontic and endodontic products).
In addition, customers have access to a wide range of services,
including software and other value-added services.
Industry Overview
In recent years, the health care industry has increasingly focused on cost containment.
This trend has benefited
distributors capable of providing a broad array of products and services at low
prices.
It also has accelerated the
growth of DSOs, GPOs, HMOs, group practices, other managed care
accounts and collective buying groups, which,
in addition to their emphasis on obtaining products at competitive prices,
tend to favor distributors capable of
providing specialized management information support.
We
believe that the trend towards cost containment has
the potential to favorably affect demand for technology solutions, including software, which
can enhance the
efficiency and facilitation of practice management.
37
Our operating results in recent years have been significantly affected by strategies
and transactions that we
undertook to expand our business, domestically and internationally, in part to address significant changes in the
health care industry, including consolidation of health care distribution companies, health care reform, trends
toward managed care, cuts in Medicare and collective purchasing arrangements.
Industry Consolidation
The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented
and diverse.
The industry ranges from sole practitioners working out of
relatively small offices to group practices
or service organizations ranging in size from a few practitioners to a large number of practitioners who have
combined or otherwise associated their practices.
Due in part to the inability of office-based health care practitioners to store and manage
large quantities of supplies
in their offices, the distribution of health care supplies and small equipment to office-based health
care practitioners
has been characterized by frequent, small quantity orders, and a need for rapid,
reliable and substantially complete
order fulfillment.
The purchasing decisions within an office-based health care practice are typically
made by the
practitioner or an administrative assistant.
Supplies and small equipment are generally purchased from more
than
one distributor, with one generally serving as the primary supplier.
The trend of consolidation extends to our customer base.
Health care practitioners are increasingly seeking to
partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician
hospital organizations.
In many cases, purchasing decisions for consolidated groups are
made at a centralized or
professional staff level; however, orders are delivered to the practitioners’ offices.
Our approach to acquisitions and joint ventures has been to expand our role as
a provider of products and services
to the health care industry.
This trend has resulted in our expansion into service areas that complement
our existing
operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired
businesses.
As industry consolidation continues, we believe that we are positioned
to capitalize on this trend, as we believe we
have the ability to support increased sales through our existing infrastructure, although
there can be no assurances
that we will be able to successfully accomplish this.
We
are focused on building relationships with decision makers
who do not reside in the office-based practitioner setting.
As the health care industry continues to change, we continually evaluate possible
candidates for joint venture or
acquisition and intend to continue to seek opportunities to expand our
role as a provider of products and services to
the health care industry.
There can be no assurance that we will be able to successfully pursue
any such
opportunity or consummate any such transaction, if pursued.
If additional transactions are entered into or
consummated, we would incur merger and/or acquisition-related costs, and there
can be no assurance that the
integration efforts associated with any such transaction would be successful.
Aging Population and Other Market Influences
The health care products distribution industry continues to experience growth
due to the aging population,
increased health care awareness, the proliferation of medical technology
and testing, new pharmacological
treatments, and expanded third-party insurance coverage, partially offset by the effects of unemployment
on
insurance coverage.
In addition, the physician market continues to benefit from the
shift of procedures and
diagnostic testing from acute care settings to alternate-care sites, particularly
physicians’ offices.
According to the U.S. Census Bureau’s International Database, between 2026 and 2036, the 45 and older
population is expected to grow by approximately 10%.
Between 2026 and 2046, this age group is expected to grow
by approximately 17%.
This compares with expected total U.S. population growth rates of
approximately 4%
between 2026 and 2036
and approximately 6% between 2026 and 2046.
According to the U.S. Census Bureau’s International Database, in 2026 there are approximately seven million
Americans aged 85 years or older, the segment of the population most in need of long-term care
and elder-care
38
services.
By the year 2050, that number is projected to increase to approximately
17 million.
The population aged
65 to 84 years is projected to increase by approximately 12% during
the same period.
As a result of these market dynamics, annual expenditures for health care services
continue to increase in the
United States.
We
believe that demand for our products and services will grow while
continuing to be impacted by
current and future operating, economic and industry conditions.
The Centers for Medicare and Medicaid Services,
or CMS, published “National Health Expenditure Data” indicating that
total national health care spending reached
approximately $5.3 trillion in 2024, or 18.0% of the nation’s gross domestic product, the benchmark measure
for
annual production of goods and services in the United States.
Health care spending is projected to reach
approximately $8.6 trillion by 2033, or 20.3% of the nation’s projected gross domestic product.
We
believe similar demographic changes are also occurring in other
markets we serve outside the U.S.
Government
Certain of our businesses involve the distribution, manufacturing, importation,
exportation, marketing, sale and/or
promotion of pharmaceuticals, medical devices and/or in vitro diagnostics
and in this regard, we are subject to
extensive local, state, federal and foreign governmental laws and regulations,
including as applicable to our
wholesale distribution of pharmaceuticals, medical devices, and in vitro diagnostics;
manufacturing activities; and
as part of our specialty home medical supplies businesses that distribute and sell
medical equipment and supplies
directly to patients.
Federal, state and certain foreign governments have also increased
enforcement activity in the
health care sector, particularly in areas of fraud and abuse, anti-bribery and anti-corruption, controlled substances
handling, medical device regulations and data privacy and security standards.
Certain of our businesses involve pharmaceuticals and/or medical devices,
including orthopaedic,
software
regulated as a medical device, and sales of medical equipment and supplies
directly to patients, that are paid for by
third parties and/or patients and must operate in compliance with a variety of burdensome
and complex coding,
billing and record-keeping requirements in order to substantiate claims
for payment under federal, state and
commercial/private health care reimbursement programs.
Government and private insurance programs fund a large portion of the total cost of medical
care, and there have
been efforts to limit such private and government insurance programs, including efforts, thus far
unsuccessful, to
seek repeal of the entire United States Patient Protection and Affordable Care Act,
as amended by the Health Care
and Education Reconciliation Act, each enacted in March 2010.
Certain of our businesses are subject to various additional federal, state,
local and foreign laws and regulations,
including with respect to the sale, transportation, importation, storage, handling
and disposal of hazardous or
potentially hazardous substances; “forever chemicals” such as per-and
polyfluoroalkyl substances; warnings related
to potential cancer or reproductive harm linked to chemicals; amalgam bans; pricing disclosures;
supply chain
transparency around human trafficking and forced labor practices; and safe working
conditions.
In addition,
activities to control medical costs, including laws and regulations lowering
reimbursement rates for
pharmaceuticals, medical devices, medical supplies and/or medical
treatments or services, are ongoing.
Laws and
regulations are subject to change and their evolving implementation may impact
our operations and financial
performance.
Certain of our businesses also maintain contracts with governmental agencies
and are subject to certain regulatory
requirements specific to government contractors.
Our businesses are generally subject to numerous laws and regulations that could
impact our financial performance,
and failure to comply with such laws or regulations could have a material
adverse effect on our businesses.
A few
noteworthy or recent items that may impact our businesses are noted below:
Effective February 2, 2026, the FDA’s
Quality Management System Regulation (QMSR) harmonizes
21 CFR Part 820 with the internationally recognized ISO 13485:2016 standard
for quality management
systems.
Concurrently, the FDA retired their QSIT inspection framework and implemented a new
inspection framework under Compliance Program 7382.850,
Inspection of Medical Device Manufacturers,
39
to align inspections with ISO’s focus on overall system effectiveness, integrated risk management, supplier
oversight, and CAPA performance.
On March 18, 2026, the Council of the EU and two European Parliament committees
adopted their joint
negotiating position on the European Commission’s November 2025 proposed
Digital Omnibus on AI
Regulation
.
Trilogue negotiations will commence among the Parliament, Council, and Commission to
agree on a final version of the text.
Any adopted changes would amend the AI Act, which has a staggered
implementation timeline running until full applicability in August 2026.
On March 26, 2026, the European Parliament formally adopted the EU Directive
on Combating Corruption,
which establishes a harmonized, criminal law framework to prevent and
combat corruption, such as bribery
in the public and private sectors, across the EU.
The Directive will enter into force on the twentieth day
following its publication in the
Official Journal of the European Union.
Member States must transpose the
Directive into local laws, regulations and administrative provisions within
two (2) years (with limited
exceptions) to reflect the Directive’s harmonized definitions of corruption-related offenses and penalty
structures.
Directive No. 2025/794 of April 14, 2025, known as the “Stop-the-Clock”
Directive, amended Directives
(EU) 2022/2464 (CSRD) by introducing a uniform two-year postponement of
the sustainability reporting
requirements for financial years beginning on or after January 1, 2025 and
on or after January 1, 2026.
It
also extends the deadline for transposing Directive (EU) 2024/1760 (CSDDD)
by one year (i.e., July 26,
2027) and the date of application of the transposed provisions depending
on the type of companies subject
to it (July 26, 2028 or July 26, 2029, as applicable).
Regulation (EU) 2025/327 of February 11, 2025 on the European Health Data Space and amending
Directive 2011/24/EU and Regulation (EU) 2024/2847 establishes the European Health Data Space
(EHDS) by providing for common rules, standards and infrastructures and a governance
framework, with a
view to facilitating access to electronic health data for the purpose of primary
use and secondary use of this
data.
This could potentially affect Henry Schein or its customers.
The U.S. has adopted new and increased tariffs on imports from countries, and
such tariffs remain subject
to frequently evolving exemptions and modifications, as well as to court challenges,
including a recent
invalidation in the Supreme Court of many of the tariffs, such as IEEPA tariffs, on February 20, 2026.
Some countries have imposed retaliatory tariffs and other restrictions on imports from the
U.S.
These
developments, and anticipated future developments, have created a
volatile environment for global trade,
and new trade policies with individual countries.
It is unclear whether, or the extent to which, the current
tariffs on trade with numerous countries will remain in place, or change, the exceptions
that may apply, and
their timing.
In the United States, the One Big Beautiful Bill Act (“OBBBA”),
signed into law on July 4, 2025, includes
a number of provisions that are expected to result in reductions in the number of
Medicaid enrollees, as
well as reductions in federal funding to state Medicaid programs, resulting
in potentially adverse impacts
on utilization of services and coverage of products.
The OBBBA also includes changes to corporate tax
rates, limitations on certain deductions and modifications to international
tax provisions.
A more detailed discussion of laws, regulations and governmental activity
is included in Management’s Discussion
and Analysis of Financial Condition and Results of Operations, contained
in our Annual Report on Form 10-K for
the fiscal year ended December 27, 2025, filed with the SEC on February
24, 2026.
40
Results of Operations
The following tables summarize the significant components of our operating
results and cash flows for the three
months ended March 28, 2026 and March 29, 2025 (in millions):
Three Months Ended
March 28,
March 29,
2026
2025
Operating results:
Net sales
$
3,368
$
3,168
Cost of sales
2,298
2,168
Gross profit
1,070
1,000
Operating expenses:
Selling, general and administrative
809
738
Depreciation and amortization
67
62
Restructuring and related costs
12
25
Operating income
$
182
$
175
Other expense, net
$
(32)
$
(30)
Income taxes
(38)
(35)
Net income
112
113
Net income attributable to Henry Schein, Inc.
107
110
Three Months Ended
March 28,
March 29,
2026
2025
Cash flows:
Net cash provided by (used in) operating activities
$
(97)
$
37
Net cash used in investing activities
(63)
(99)
Net cash provided by financing activities
120
89
Plan of Restructuring and Related Costs
On August 6, 2024, we committed to a restructuring plan (the “2024
Plan”) to integrate our acquisitions, right-size
operations and further increase efficiencies.
We currently expect this plan to be completed by the end of 2027.
During the three months ended March 28, 2026 and March 29, 2025, we recorded
restructuring and related charges
associated with the 2024 Plan of $12 million and $25 million, respectively.
The restructuring and related costs for
these periods primarily related to severance and employee-related costs,
costs to exit facilities and other exit costs.
We expect to record restructuring and related charges associated with the 2024 Plan through the end of 2027;
however, an estimate of the amount of these charges for 2026 through 2027 has not yet been determined.
During the quarter ended March 28, 2026, in connection with the
2024 Plan, we recorded a loss of $2 million
related to the disposal of businesses in the Global Specialty Products
segment.
This amount is included in the $12
million of restructuring and related charges discussed above.
41
Three Months Ended March 28, 2026 Compared to Three Months Ended March 29, 2025
Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other
Expense, Net; and Income Taxes are
based on actual values and may not recalculate due to rounding.
Our reportable segments are determined based on how our Chief Executive
Officer manages the business, assesses
performance and allocates resources.
We have three reportable segments:
(i) Global Distribution and Value-Added
Services; (ii) Global Specialty Products; and (iii) Global Technology.
Net Sales
Net sales by reportable segment and by major product or service type were
as follows:
March 28,
% of
March 29,
% of
Increase / (Decrease)
2026
Total
2025
Total
$
%
Global Distribution and Value
-Added Services
Global Dental Merchandise
(1)
$
1,292
38.4
%
$
1,185
37.4
%
$
107
9.0
%
Global Dental Equipment
(2)
417
12.4
384
12.1
33
8.6
Global Value
-Added Services
(3)
57
1.7
52
1.7
5
10.6
Global Dental
1,766
52.5
1,621
51.2
145
9.0
Global Medical
(4)
1,073
31.8
1,055
33.3
18
1.7
Total Global Distribution and Value
-Added Services
2,839
84.3
2,676
84.5
163
6.1
Global Specialty Products
(5)
397
11.8
367
11.6
30
8.1
Global Technology
(6)
173
5.1
162
5.1
11
7.0
Eliminations
(41)
(1.2)
(37)
(1.2)
(4)
n/a
Total
$
3,368
100.0
%
$
3,168
100.0
%
$
200
6.3
(1)
Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum,
acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise.
(2)
Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair
services and high-tech and digital restoration equipment.
(3)
Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.
(4)
Includes branded and generic pharmaceuticals, home solutions products, vaccines, surgical products, diagnostic tests, infection-
control products, X-ray products, equipment, PPE products, and vitamins.
(5)
Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and
orthopedic products and other health care-related products and services.
(6)
Consists of the development and distribution of practice management software, e-services and other technology-enabled products
for health care providers.
The components of our sales growth were as follows:
Constant Currency
Growth/(Decline)
Total Constant
Currency Growth
Foreign
Exchange
Impact
Total Sales
Growth
Local Internal
Growth
Acquisition
Growth/
(Decline)
Global Distribution and Value
-Added Services
Global Dental Merchandise
3.0
%
1.2
%
4.2
%
4.8
%
9.0
%
Global Dental Equipment
3.5
-
3.5
5.1
8.6
Global Value
-Added Services
7.8
1.2
9.0
1.6
10.6
Global Dental
3.2
1.0
4.2
4.8
9.0
Global Medical
1.3
0.1
1.4
0.3
1.7
Total Global Distribution and Value
-Added Services
2.5
0.6
3.1
3.0
6.1
Global Specialty Products
1.7
1.7
3.4
4.7
8.1
Global Technology
6.9
(1.3)
5.6
1.4
7.0
Total
2.5
0.7
3.2
3.1
6.3
42
Global Sales
Global net sales for the three months ended March 28, 2026 increased 6.3%,
attributable to internal growth of 2.5%,
acquisition growth of 0.7%, and an increase in foreign exchange of 3.1%.
The components of our sales increase are
presented in the table above.
Global Distribution and Value-Added Services Sales
Global Distribution and Value-Added Services net sales for the three months ended March 28, 2026 increased
6.1%.
The components of our sales increase are presented in
the table above.
The 3.2% increase in internally generated local currency dental sales was
primarily due to sales growth in U.S.,
growth in traditional dental equipment in the U.S. and international
markets, and value-added services sales
attributable to increased sales in our practice transitions business.
The 1.3% increase in internally generated local currency medical sales was
attributable to growth of our Home
Solutions business and dialysis products,
partially offset by lower point of care diagnostic test products related to
respiratory illness.
Global Specialty Products Sales
Global Specialty Products net sales for the three months ended March
28, 2026 increased 8.1%.
The components
of our sales increase are presented in the table above.
The 1.7% increase in internally generated local currency sales was attributable
to growth in our value implant and
biomaterial businesses.
Global Technology Sales
Global Technology net sales for the three months ended March 28, 2026 increased 7.0%.
The components of sales
growth are presented in the table above.
The internally generated local currency increase of 6.9% in Global Technology sales was primarily attributable to
the adoption of our core practice management solutions, particularly
our cloud-based platforms.
Gross Profit
Gross profit and gross margin percentages by segment and in total were as follows:
March 28,
Gross
March 29,
Gross
Increase / (Decrease)
2026
Margin %
2025
Margin %
$
%
Global Distribution and Value
-Added Services
$
732
25.8
%
$
681
25.4
%
$
51
7.6
%
Global Specialty Products
220
55.3
206
56.0
14
6.7
Global Technology
119
68.6
110
67.9
9
8.2
Corporate
(1)
n/a
3
n/a
(4)
n/a
Total
$
1,070
31.8
$
1,000
31.6
$
70
7.1
Gross margin may not be comparable to that of other distribution companies due to
differing industry practices in
the classification of distribution network costs.
Gross margin percentages also vary across our segments, reflecting
differences in business models.
The Global Specialty Products segment generates
higher gross margins, as it
primarily includes products we develop and manufacture, compared
to the Global Distribution and Value-Added
Services segment, which principally distributes third-party and corporate brand
products.
While the Global
Specialty Products segment has increasingly leveraged the Global
Distribution and Value-Added Services segment
as a sales channel, the impact on overall margins has not been material.
The Global Technology segment also
generates higher gross margins, reflecting our role as both developer and provider of
software products and
services.
43
Within our Global Distribution and Value
-Added Services segment, gross profit margins may fluctuate between the
periods as a result of the changes in product mix and customer mix.
With respect to customer mix, sales to our
large-group customers are typically completed at lower gross margins as a result of
higher sales volumes, while
sales to office-based practitioners generally carry higher gross margins due to lower volumes.
The increase in Global Distribution and Value-Added Services gross profit for the three months ended March 28,
2026 compared to the prior-year-period is due primarily to increased internally generated sales volume
as described
above.
The increase in gross margin rates was attributable primarily to the impact
of higher gross margins in the
Global Distribution and Value-added Services and Global Technology
businesses as well as favorable business
mix.
The increase in Global Specialty Products gross profit primarily reflects
increased internally generated sales
volume and gross profit from acquisitions.
The decrease in gross margin rates was due to product mix.
The increase in Global Technology gross profit is the result primarily of higher internally generated sales.
The
increase in gross margin rates was due to product mix.
Operating Expenses
Operating expenses (consisting of selling, general and administrative
expenses; depreciation and amortization; and
restructuring and related costs) by segment were as follows:
% of
% of
March 28,
Respective
March 29,
Respective
Increase / (Decrease)
2026
Sales
2025
Sales
$
%
Global Distribution and Value
-Added Services
$
549
19.4
%
$
514
19.2
%
$
35
7.0
%
Global Specialty Products
162
40.7
150
40.7
12
8.2
Global Technology
73
41.8
68
42.1
5
6.4
Corporate
33
n/a
38
n/a
(5)
n/a
817
24.3
770
24.3
47
6.1
Adjustments
(1)
71
n/a
55
n/a
16
n/a
Total operating expenses
$
888
26.4
$
825
26.0
$
63
7.8
(1)
Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.
These
items may vary independently of business performance.
Please see
.
These adjustments (current quarter vs. prior
quarter) consist of (i) acquisition intangible amortization ($45 million vs. $43 million), (ii) restructuring and related costs ($12 million
vs. $25 million), (iii) change in contingent consideration ($1
million vs. $(2) million), (iv) cyber incident-insurance proceeds, net of
third-party advisory expenses (no activity) vs. $(20) million net proceeds), (v) impairment of intangible assets (no activity) vs. $1
million),
and (vi) costs associated with shareholder advisory matters and implementation related select value creation consulting costs
($13 million vs. $8 million).
The net increase in operating expenses was
attributable to the following:
Operating Costs
(excluding
acquisitions)
Acquisitions
Adjustments
Total
Global Distribution and Value
-Added Services
$
30
$
5
$
-
$
35
Global Specialty Products
6
6
-
12
Global Technology
5
-
-
5
Corporate
(5)
-
-
(5)
36
11
-
47
Adjustments
-
-
16
16
Total operating expenses
$
36
$
11
$
16
$
63
The components of the net increase in total operating expenses are presented
in the table above.
The increase in
operating costs (excluding acquisitions) during the three months ended
March 28, 2026 was primarily attributable
to unfavorable impact of foreign exchange rates.
During the three months ended March 28, 2026, our operating
costs were favorably impacted by the remeasurement to the fair value
of a previously held equity investment of $11
million within our Global Specialty Products segment.
During the three months ended March 29, 2025, our
operating costs were favorably impacted by insurance proceeds of $20 million
related to the October 2023 cyber
incident included in the Adjustments category.
44
Other Expense, Net
Other expense, net was as follows:
March 28,
March 29,
Variance
2026
2025
$
%
Interest income
$
7
$
6
$
1
21.8
%
Interest expense
(39)
(35)
(4)
(12.6)
Other, net
-
(1)
1
n/a
Other expense, net
$
(32)
$
(30)
$
(2)
(8.0)
Interest income increased primarily due to increased interest rates.
Interest expense increased primarily due to
increased borrowings.
Income Taxes
Our effective tax rate was 25.5% for the three months ended March 28, 2026, compared
to 24.9% for the prior year
period.
The difference between our effective and federal statutory tax rates primarily relates to state
and foreign
income taxes and interest expense.
45
Liquidity and Capital Resources
Our principal capital requirements have included funding of acquisitions, purchases
of additional noncontrolling
interests, repayments of debt principal, the funding of working capital needs,
purchases of fixed assets and
repurchases of common stock.
Working capital requirements generally result from increased sales, special
inventory forward buy-in opportunities and payment terms for receivables
and payables.
Historically, sales have
tended to be stronger during the second half of the year and special inventory
forward buy-in opportunities have
been most prevalent just before the end of the year, and have caused our working capital requirements
to be higher
from the end of the third quarter to the end of the first quarter of
the following year.
We finance our business primarily through cash generated from our operations, revolving credit facilities and debt
placements.
Please see
for further information.
Our ability to generate sufficient cash flows from
operations is dependent on the continued demand of our customers
for our products and services, and access to
products and services from our suppliers.
Our business requires a substantial investment in working capital, which
is susceptible to fluctuations during the
year as a result of inventory purchase patterns and seasonal demands.
Inventory purchase activity is a function of
sales activity, special inventory forward buy-in opportunities and our desired level of inventory.
We finance our business to provide adequate funding for at least 12 months.
Funding requirements are based on
forecasted profitability and working capital needs, which, on occasion, may
change.
Consequently, we may change
our funding structure to reflect any new requirements.
Our acquisition strategy is focused on investments in companies,
including high growth high margin businesses
aligned with our BOLD+1 strategy, that add new customers and sales teams, increase our geographic footprint
(whether entering a new country, such as emerging markets, or building scale where we have already invested in
businesses), and finally, those that enable us to access new products and technologies.
We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets,
and our available funds under existing credit facilities provide us with
sufficient liquidity to meet our currently
foreseeable short-term and long-term capital needs.
Net cash used in operating activities was $97 million for the three months
ended March 28, 2026, compared to net
cash provided by operating activities of $37 million for the prior year.
The net change of $134 million was
primarily attributable to changes in working capital accounts (primarily
accounts receivable, inventory, and
accounts payable and accrued expenses), partially offset by an increase in operating
income.
Net cash used in investing activities was $63 million for the three months
ended March 28, 2026, compared to net
cash used in investing activities of $99 million for the prior year.
The net change of $36 million was primarily
attributable to lower acquisition activity.
Net cash provided by financing activities was $120 million for the
three months ended March 28, 2026, compared
to net cash provided by financing activities of $89 million for the prior
year.
The net change of $31 million was
primarily due to a reduction in acquisitions of noncontrolling interests
in subsidiaries, and decreased repurchases of
common stock, partially offset by decreased net borrowings.
46
The following table summarizes selected measures of liquidity and capital
resources:
March 28,
December 27,
2026
2025
Cash and cash equivalents
$
138
$
156
Working
capital
(1)
1,199
1,236
Debt:
Bank credit lines
$
1,046
$
764
Current maturities of long-term debt
35
33
Long-term debt
2,327
2,310
Total debt
$
3,408
$
3,107
Leases:
Current operating lease liabilities
$
78
$
78
Non-current operating lease liabilities
263
251
(1)
Includes $442 million and $491 million of certain accounts receivable which serve as security for U.S. trade accounts receivable
securitization at March 28, 2026 and December 27, 2025, respectively.
Our cash and cash equivalents consist of bank balances and investments
in money market funds representing
overnight investments with a high degree of liquidity.
Accounts receivable days sales outstanding and inventory turns
Our accounts receivable days sales outstanding from operations
increased to 45.7 days as of March 28, 2026 from
44.1 days as of March 29, 2025.
During the three months ended March 28, 2026, we wrote
off approximately $5
million of fully reserved accounts receivable against our trade receivable
reserve.
Our inventory turns from
operations decreased to 4.6 as of March 28, 2026 from 4.8 as of March 29, 2025.
Our working capital accounts
may be impacted by current and future economic conditions.
Leases
We
have operating and finance leases for corporate offices, office space, distribution and other
facilities, vehicles
and certain equipment.
Our leases have remaining terms of less than one year to approximately
22 years, some of
which may include options to extend the leases for up to 10 years.
As of March 28, 2026, our right-of-use assets
related to operating leases were $312 million and our current and non-current
operating lease liabilities were $78
million and $263 million, respectively.
Stock Repurchases
On January 27, 2025, our Board of Directors authorized the repurchase
of up to an additional $500 million in shares
of our common stock.
On May 19, 2025, we executed an accelerated share repurchase program
to repurchase a total of $250 million of
our outstanding common stock based on volume-weighted average
prices.
In May 2025, we received 3,122,832
shares at an estimated fair value of $224
million.
In July 2025, we received an additional 368,651 shares at an
estimated fair value of $26 million, representing the final amount of shares
to be received under this accelerated
share repurchase program.
On September 8, 2025, our Board of Directors authorized the repurchase of
up to an additional $750 million in
shares of our common stock.
From March 3, 2003 through March 28, 2026, we repurchased $6.1 billion, or
109,486,614 shares,
under our
common stock repurchase programs, with $655 million available
as of March 28, 2026 for future share repurchases.
47
Redeemable Noncontrolling Interests
Some minority stockholders in certain of our subsidiaries have the right,
at certain times, to require us to acquire
their ownership interest in those entities at fair value.
Accounting Standards Codification Topic 480-10 is
applicable for noncontrolling interests where we are or may be required
to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling
interest holder under the terms of a put
option contained in contractual agreements.
As of March 28, 2026 and December 27, 2025, our balance
for
redeemable noncontrolling interests was $903 million and $895 million,
respectively.
Please see
for further information.
Critical Accounting Estimates
There have been no material changes in our critical accounting estimates
from those disclosed in Item 7 of our
Annual Report on Form 10-K for the year ended December 27, 2025.
Accounting Standards Update
For a discussion of accounting standards updates that have been adopted
or will be adopted, see
of the Notes to the Condensed Consolidated Financial Statements
included under Item 1.
ITEM 3.
QUANTITATIVE
AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK
There have been no material changes in our exposure to market risk
from that disclosed in Item 7A of our Annual
Report on Form 10-K for the year ended December 27, 2025.
48
ITEM 4.
CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of management, including
our principal executive officer and
principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and
procedures as of the end of the period covered by this quarterly report
as such term is defined in Rules 13a-15(e)
and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”).
Based
on this evaluation, our management, including our principal executive
officer and principal financial officer,
concluded that our disclosure controls and procedures were effective as of March
28, 2026, to ensure that all
material information required to be disclosed by us in reports that we file
or submit under the Exchange Act is
accumulated and communicated to them as appropriate to allow timely
decisions regarding required disclosure and
that all such information is recorded, processed, summarized and reported
within the time periods specified in the
SEC’s rules and forms, and the rules of the Nasdaq stock exchange.
Changes in Internal Control over Financial Reporting
The combination of acquisitions, continued acquisition integrations and system
implementation activity undertaken
during the quarter ended March 28, 2026, and carried over from prior quarters,
when considered in the aggregate,
represents a material change in our internal control over financial reporting.
During the quarter ended March 28, 2026, we completed the acquisition
of a controlling interest of a Global
Specialty Products segment affiliate and a Global Distribution and Value-Added Services segment business in the
U.S.
Also, post-acquisition integration related activities continued for businesses
acquired during prior quarters
within our Global Specialty Products segment.
These acquisitions, the majority of which utilize separate
information and financial accounting systems, have been included
in our condensed consolidated financial
statements since their respective dates of acquisition.
Additionally, during the quarter ended March 28, 2026, we continued systems implementation activities for the
phased roll-out of a new e-commerce system for our Global Distribution
and Value
-Added Services segment in the
U.S. and Canada.
All acquisitions, continued acquisition integrations, and system implementation
activities involve necessary and
appropriate change-management controls that are considered in our quarterly
assessment of the design and
operating effectiveness of our internal control over financial reporting.
Limitations of the Effectiveness of Internal Control
A control system, no matter how well conceived and operated, can provide
only reasonable, not absolute, assurance
that the objectives of the internal control system are met.
Because of the inherent limitations of any internal control
system, no evaluation of controls can provide absolute assurance that
all control issues, if any, within a company
have been detected.
49
PART
II.
OTHER INFORMATION
ITEM 1.
LEGAL PROCEEDINGS
For a discussion of Legal Proceedings, see
of the Notes to the Condensed
Consolidated Financial Statements included under Item 1.
ITEM 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in
Part I, Item 1A, of our Annual Report on
Form 10-K for the year ended December 27, 2025.
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS
Purchases of Equity Securities by the Issuer
Our share repurchase program, announced on March 3, 2003, originally
allowed us to repurchase up to two million
shares pre-stock splits (eight million shares post-stock splits) of our common
stock, which represented
approximately 2.3% of the shares outstanding at the commencement
of the program.
Subsequent additional
increases since 2003 that have aggregated to an additional $6.7 billion,
authorized by our Board, to the repurchase
program provide for a total of $6.8 billion (including $500 million authorized on
January 27, 2025 and an
additional $750 million authorized on September 8, 2025) of shares of our common
stock to be repurchased under
this program,
with $655 million currently available for future share repurchases.
On May 19, 2025, we executed an accelerated share repurchase program to
repurchase a total of $250 million of
our outstanding common stock based on volume-weighted average prices.
In May 2025 we received 3,122,832
shares at an estimated fair value of $224 million.
In July 2025, we received an additional 368,651 shares at an
estimated fair value of $26 million, representing the final amount of shares
to be received under this accelerated
share repurchase program.
As of March 28, 2026, we had repurchased approximately $6.1 billion of
common stock (109,486,614)
shares
under these initiatives,
with $655 million available for future share repurchases.
The following table summarizes repurchases of our common stock
under our stock repurchase program during the
fiscal quarter ended March 28, 2026:
Total Number
Maximum Number
Total
of Shares
of Shares
Number
Average
Purchased as Part
that May Yet
of Shares
Price Paid
of Our Publicly
Be Purchased Under
Fiscal Month
Purchased (1)
Per Share
Announced Program
Our Program (2)
12/28/2025 through 1/31/2026
720,444
$
77.25
720,444
9,595,535
2/1/2026 through 2/28/2026
565,846
78.37
565,846
8,252,525
3/1/2026 through 3/28/2026
323,696
77.23
323,696
9,083,576
1,609,986
1,609,986
(1)
All repurchases were executed in the open market under our existing publicly announced authorized program.
(2)
The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the
closing price of our common stock at that time.
This table excludes shares withheld from employees to satisfy minimum tax withholding
requirements for equity-based transactions.
50
ITEM 6.
EXHIBITS
101.INS
Inline XBRL Instance Document - the instance document does not appear
in the
Interactive Data File because its XBRL tags are embedded within the Inline
XBRL document+
101.SCH
Inline XBRL Taxonomy Extension Schema Document+
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document+
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document+
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document+
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document+
104
The cover page of Henry Schein, Inc.’s Quarterly Report on Form 10-Q for the
quarter ended March 28, 2026, formatted in Inline XBRL (included within
Exhibit 101 attachments).+
_________
+ Filed or furnished herewith.
** Indicates management contract or compensatory plan or agreement.
51
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
Henry Schein, Inc.
(Registrant)
By: /s/ RONALD N. SOUTH
Ronald N. South
Senior Vice President and
Chief Financial Officer
(Authorized Signatory and Principal Financial
and Accounting Officer)
Dated: May 5, 2026

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Frederick M. Lowery, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Henry Schein, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 5, 2026   

/s/ Frederick M. Lowery

   Frederick M. Lowery
   Chief Executive Officer

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Ronald N. South, certify that:

 

1.  I have reviewed this quarterly report on Form 10-Q of Henry Schein, Inc.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 5, 2026   

/s/ Ronald N. South

   Ronald N. South
   Senior Vice President and
   Chief Financial Officer

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Henry Schein, Inc. (the “Company”) for the period ending March 28, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frederick M. Lowery, the Chief Executive Officer of the Company, and I, Ronald N. South, Senior Vice President and Chief Financial Officer of the Company, do hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  

/s/ Frederick M. Lowery

Dated: May 5, 2026   

Frederick M. Lowery

Chief Executive Officer

Dated: May 5, 2026   

/s/ Ronald N. South

  

Ronald N. South

Senior Vice President and

Chief Financial Officer

This certification accompanies each Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 99.1

FORM OF

RESTRICTED STOCK UNIT AGREEMENT

PURSUANT TO THE

HENRY SCHEIN, INC. 2024 STOCK INCENTIVE PLAN

(AS AMENDED AND RESTATED EFFECTIVE AS OF MAY 21, 2024)

THIS AGREEMENT (the “Agreement”) is made as of [Grant Date] (the “Grant Date”), by and between Henry Schein, Inc. (the “Company”) and [Participant Name] (the “Participant”). Additional country-specific and state-specific terms and conditions that govern the grant made hereunder are attached hereto on Annex 1, which terms and conditions are incorporated by reference herein and made a part of the Agreement.

W I T N E S S E T H:

WHEREAS, the Company has adopted the Henry Schein, Inc. 2024 Stock Incentive Plan (as amended and restated effective as of May 21, 2024), as amended from time to time (the “Plan”) (a copy of which is on file with the Company’s Corporate Human Resources Department and is available for the Participant to review upon request at reasonable intervals as determined by the Company), which is administered by the Compensation Committee (the “Committee”) of the Company’s Board of Directors (the “Board”);

WHEREAS, pursuant to Section 9(d) of the Plan, the Committee may grant Restricted Stock Units to Key Employees under the Plan;

WHEREAS, the shares of the Company’s common stock are traded on the Nasdaq Stock Market under the symbol “HSIC”; and

WHEREAS, the Participant is a Key Employee of the Company or a Subsidiary.

NOW, THEREFORE, for and in consideration of the mutual promises herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. Grant of Restricted Stock Units.

Subject to the restrictions and other conditions set forth herein, in the Plan and Annex 1, the Committee has authorized this grant of [Shares Granted] Restricted Stock Units to the Participant on the Grant Date.

2. Vesting and Payment.

(a) Vesting Schedule. Except as set forth in Sections 2(c) and 2(d), one-fourth (1/4) of the Restricted Stock Units granted hereunder shall automatically and immediately vest on each of the first, second, third and fourth anniversaries of the Grant Date (each a “Scheduled Payment Date”); provided that the Participant has not had a Termination of Employment at any time prior to the applicable Scheduled Payment Date.

(b) No Proportionate or Partial Vesting. Except as set forth in Section 2(c), there shall be no proportionate or partial vesting in the periods prior to the applicable Scheduled Payment Date and all vesting shall occur only on the applicable Scheduled Payment Date; provided that no Termination of Employment has occurred prior to the applicable Scheduled Payment Date.

(c) Retirement. The unvested Restricted Stock Units shall vest on a pro-rated basis upon the Participant’s Retirement, unless otherwise provided expressly in a written agreement between the Participant and the Company (or a Subsidiary). For purposes of this Section 2(c), the Participant shall qualify for “Retirement” if (i) the Participant’s age (minimum 55) plus years of service with the Company and its Subsidiaries equal or exceed 70, (ii) the Participant has provided written notice of the Participant’s retirement to the Company at least 30 days prior to the date of such retirement, and (iii) no Termination of Employment has occurred prior to the date of such retirement. For purposes of determining the age and service requirement under Section 2(c)(i), the Participant’s age and years of service shall be determined by the Participant’s most recent birthday and employment anniversary, respectively. For purposes of this Section 2(c), vesting on a pro-rated basis shall be calculated by multiplying the number of unvested Restricted Stock Units, the numerator of which is the number of days from the Grant Date to the date of the Participant’s Retirement, and the denominator of which is the number of days from the Grant Date to the fourth anniversary of the Grant Date.

Form 2

3/2026


(d) Change in Control Termination, Disability and Death. The Restricted Stock Units shall become fully vested on the earliest of (i) a Termination of Employment by the Company (or a Subsidiary) without Cause occurring within the 2-year period following a Change of Control, (ii) the Participant’s Disability and (iii) the Participant’s death; provided that no Termination of Employment has occurred prior to any such event, unless otherwise provided expressly in a written agreement between the Participant and the Company (or a Subsidiary). For purposes of this Agreement, “Cause” shall have the meaning set forth in Section 7(b) of the Plan, but shall also include any breach by the Participant of any agreement with the Company or any of its Subsidiaries. For purposes of this Agreement, a “Change of Control” shall mean a Change of Control as defined in the Plan. For purposes of this Agreement, “Disability” shall mean the approval of, and receiving benefits for, long term disability by the disability insurance carrier under the Company’s (or if applicable, Subsidiary’s) long term disability plan.

(e) Payment. The Participant shall be entitled to receive one share of Common Stock with respect to one vested Restricted Stock Unit. The Participant shall be paid one share of Common Stock with respect to each vested Restricted Stock Unit within thirty (30) days of the applicable Scheduled Payment Date; except that, in the event of (i) Retirement, (ii) a Termination of Employment by the Company (or a Subsidiary) without Cause occurring within the 2-year period following a Change of Control, (iii) death or (iv) Disability, the Participant shall be paid within thirty (30) days of such Retirement, Termination of Employment, death or Disability, subject to Section 18 set forth in Annex 1 to the extent applicable, including with respect to a Participant who qualifies for Retirement at any time following the Grant Date.

3. Forfeiture and Recoupment.

(a) Forfeiture on Termination. Subject to Section 2 above, all unvested Restricted Stock Units will be forfeited on the Participant’s Termination of Employment.

(b) Forfeiture due to Cause Conduct. Notwithstanding anything herein or in the Plan to the contrary, in the event that the Participant engages in conduct that could reasonably be expected to constitute Cause, as defined in Section 2(d) above (regardless of whether the Participant had a Termination of Employment), as determined by the Company in its sole discretion, at any time on or after the Grant Date and prior to the applicable settlement date set forth in Section 2 above (such applicable settlement date, the “Payment Date”) the Committee shall have the right, in its sole discretion, to cause the immediate forfeiture of all the Restricted Stock Units (including any dividends credited thereupon) (whether or not vested) in their entirety, in which case the Participant shall have no further rights or interests with respect to such Restricted Stock Units (including any such dividends).

(c) Forfeiture Following Competitive Activity. Notwithstanding anything herein or in the Plan to the contrary, the grant of Restricted Stock Units (including any dividends credited thereupon) provided for under this Agreement is conditioned on the Participant not engaging in any Competitive Activity (as defined below) from the date that is twelve (12) months prior to the Payment Date through the first anniversary of such Payment Date. If, on or after the date that is twelve (12) months prior to the Payment Date but prior to the Payment Date, the Participant engages in a Competitive Activity, the Committee shall have the right, in its sole discretion, to cause the immediate forfeiture of all of the Restricted Stock Units (including any dividends credited thereupon) (whether or not vested) in their entirety, in which case the Participant shall have no further rights or interests with respect to such Restricted Stock Units (including any such dividends).

(d) Recoupment Following Cause Conduct or Competitive Activity After Payment Date. In the event that (i) the Participant engages in conduct described under Section 3(b) on or after the Payment Date, but on or prior to the first anniversary of such Payment Date or (ii) the Participant engages in a Competitive Activity on or after the Payment Date but on or prior to the first anniversary of such Payment Date, in each case, the Company shall have the right to recoup, in its sole discretion, from the Participant, and the Participant shall repay to the Company, within thirty (30) days following demand by the Company, a payment equal to the Fair Market Value of the aggregate shares of Common Stock payable in respect of such Restricted Stock Units (including any dividends credited thereupon) on the Payment Date (including any dividends or other distributions thereafter paid thereon); provided, that, the Company may require the Participant to satisfy such payment obligations hereunder either by forfeiting and returning to the Company such shares of Common Stock, Restricted Stock Units, dividends or any other shares of Common Stock, or making a cash payment or any combination of these methods, as determined by the Company in its sole discretion. The Company and its Subsidiaries, in their sole discretion, shall have the right to set off (or cause to be set off) any amounts otherwise due to the Participant from the Company (or the applicable Subsidiary) in satisfaction of such repayment obligation, provided that any such amounts are exempt from, or set off in a manner intended to comply with, the requirements of any applicable law (including, without limitation, Section 409A of the Code).

 

2


(e) Participant Acknowledgement of Reasonableness. The Participant hereby acknowledges and agrees that the forfeiture and recoupment conditions set forth in this Section 3, in view of the nature of the business in which the Company and its affiliates are engaged, are reasonable in scope and necessary in order to protect the legitimate business interests of the Company and its affiliates, and that any violation thereof would result in irreparable harm to the Company and its affiliates. The Participant also acknowledges and agrees that (i) it is a material inducement and condition to the Company’s issuance of the Restricted Stock Units (including any dividends credited thereupon) that such Participant agrees to be bound by such forfeiture and recoupment conditions and, further, that the amounts required to be forfeited or repaid to the Company pursuant to forfeiture and recoupment conditions set forth above are reasonable, and (ii) nothing in this Agreement or the Plan is intended to preclude the Company (or any affiliate thereof) from seeking any remedies available at law, in equity, under contract to the Company or otherwise, and the Company (or any affiliate thereof) shall have the right to seek any such remedy with respect to the Restricted Stock Units, any dividends credited thereupon, or otherwise.

(f) Definition of Competitive Activity. For purposes of this Agreement, the Participant will be deemed to engage in a “Competitive Activity” if, either directly or indirectly, without the express prior written consent of the Company, the Participant (i) takes other employment with, renders services to, or otherwise engages in any business activities with, companies or other entities that are competitors of the Company or any of its affiliates, (ii) solicits or induces, or in any manner attempts to solicit or induce, any person employed by or otherwise providing services to the Company or any of its affiliates, to terminate such person’s employment or service relationship, as the case may be, with the Company or any of its affiliates, (iii) diverts, or attempts to divert, any person or entity from doing business with the Company or any of its affiliates or induces, or attempts to induce, any such person or entity from ceasing to be a customer or other business partner of the Company or any of its affiliates, (iv) violates any agreement between the Participant and the Company or any of its affiliates relating to the non-disclosure of proprietary or confidential information of the Company or any of its affiliates, and/or (v) conducts himself or herself in a manner adversely affecting the Company or any of its affiliates, including, without limitation, making false, misleading or negative statements, either orally or in writing, about the Company or any of its affiliates. The determination as to whether the Participant has engaged in a Competitive Activity shall be made (A) if the Participant is an executive officer of the Company, by the Committee in its sole discretion or (B) if the Participant is not an executive officer of the Company, by the Company in its sole discretion.

(g) Protected Rights. Nothing in this Agreement shall be construed (i) to prohibit or is intended to restrict or impede the Participant from discussing the terms and conditions of the Participant’s employment with coworkers or exercising protected rights under Section 7 of the National Labor Relations Act or (ii) to prohibit the Participant from reporting possible violations of federal or state law or making other disclosures that are protected under whistleblower or other provisions of any applicable federal or state law or regulations; further, nothing herein prevents the Participant from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that a Participant has reason to believe is unlawful. In addition, the Participant is hereby advised as follows pursuant to the Defend Trade Secrets Act: An individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (I) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (II) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.

(h) Clawback Policies. This Section 3(h) applies solely with respect to Participants who are members of the Company’s Executive Management Committee. Notwithstanding anything herein to the contrary, to the extent applicable to the Participant, by accepting the Restricted Stock Units granted under this Agreement, the Participant agrees and acknowledges that the Restricted Stock Units awarded under this Agreement (including the underlying shares) (whether or not vested) shall be subject to, and the Participant agrees to abide by, the terms and conditions of (i) the Company’s Incentive Compensation Recoupment Policy, (ii) the Company’s Dodd-Frank Clawback Policy and (iii) any other clawback and/or recoupment policy approved by the Board (or any committee thereof) from time to time, in each case, as amended from time to time and to the extent set forth in each applicable policy. To the extent that the Participant is subject to the terms and conditions of any of the foregoing Company clawback policies, the Participant shall have signed or shall sign each applicable clawback policy acknowledgement provided by the Company either in connection with the execution of this Agreement or prior to the Participant’s execution of this Agreement; provided, that the Participant’s failure to sign such acknowledgement shall have no impact on the applicability or enforceability of such Company clawback policy.

4. Dividend Equivalents. Cash dividends on shares of Common Stock shall be credited to a dividend book entry account on behalf of the Participant with respect to each Restricted Stock Unit granted to a Participant, provided that such cash dividends shall not be deemed to be reinvested in shares of Common Stock and will be held uninvested and without interest and paid in cash if and when the Restricted Stock Unit vests. Stock dividends on shares of Common Stock shall be credited to a dividend book entry account on behalf of the Participant with respect to each Restricted Stock Unit granted to a Participant, provided that the Participant shall not be entitled to such dividend unless and until the Restricted Stock Unit vests.

 

3


5. Rights as a Stockholder. The Participant shall have no rights as a stockholder with respect to any shares covered by any Restricted Stock Unit unless and until the Participant has become the holder of record of the shares, and no adjustments shall be made for dividends in cash or other property, distributions or other rights in respect of any such shares, except as otherwise specifically provided for in this Agreement or the Plan.

6. Withholding. The Participant shall pay, or make arrangements to pay, in a manner satisfactory to the Company, an amount equal to the amount of all applicable foreign, federal, state, provincial and local taxes that the Company is required to withhold at any time (“Tax-Related Items”). In the absence of such arrangements, the Company or one of its Subsidiaries shall have the right to withhold such taxes from the Participant’s normal pay or other amounts payable to the Participant. In addition, any statutorily required withholding obligation may be satisfied, in whole or in part, at the Participant’s election, in the form and manner prescribed by the Committee, by delivery of shares of Common Stock (including shares issuable under this Agreement).

7. Provisions of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan, including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. Capitalized terms in this Agreement that are not otherwise defined shall have the same meaning as set forth in the Plan. Subject to Section 3, if and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes any prior agreements between the Company and the Participant with respect to the subject matter hereof.

8. Amendment. To the extent applicable, the Board or the Committee may at any time and from time to time amend, in whole or in part, any or all of the provisions of this Agreement to comply with any applicable laws and stock exchange rules and regulations (including, without limitation, Section 409A of the Code and the regulations thereunder) and may also amend, suspend or terminate this Agreement subject to the terms of the Plan. Except as otherwise provided in the Plan, no modification or waiver of any of the provisions of this Agreement shall be effective unless in writing and signed by the party against whom it is sought to be enforced.

9. Notices. Any notice or communication given hereunder shall be in writing and shall be deemed to have been duly given when delivered in person, or by regular United States mail or similar foreign mail or post, first class and prepaid, to the appropriate party at the address set forth below (or such other address as the party shall from time to time specify):

If to the Company, to:

Henry Schein, Inc.

135 Duryea Road

Melville, New York 11747

Attention: General Counsel

If to the Participant, to the address on file with the Company.

10. No Obligation to Continue Employment or Services. This Agreement is not an agreement of employment, consultancy or directorship. This Agreement does not guarantee that the Company or its Subsidiaries will employ or retain, or continue to employ or retain, the Participant during the entire, or any portion of the, term of this Agreement, including but not limited to any period during which any Restricted Stock Unit is outstanding, nor does it modify in any respect the Company or its Subsidiaries’ right to terminate or modify the Participant’s employment, service relationship or compensation.

11. Legend. The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates representing shares of Common Stock issued pursuant to this Agreement. The Participant shall, at the request of the Company, promptly present to the Company any and all certificates representing shares of Common Stock acquired pursuant to this Agreement in the possession of the Participant in order to carry out the provisions of this Section.

12. Securities Representations. The grant of the Restricted Stock Units and issuance of shares of Common Stock upon vesting of the Restricted Stock Units shall be subject to, and in compliance with, all applicable requirements of federal, state or foreign securities law. No shares of Common Stock may be issued hereunder if the issuance of such shares of Common Stock would constitute a violation of any applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the shares of Common Stock may then be listed. As a condition to the settlement of the Restricted Stock Units, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation.

 

4


The shares of Common Stock are being issued to the Participant and this Agreement is being made by the Company in reliance upon the following express representations and warranties of the Participant. The Participant acknowledges, represents and warrants that:

(a) He or she has been advised that he or she may be an “affiliate” within the meaning of Rule 144 under the Securities Act of 1933, as amended (the “Act”) and in this connection the Company is relying in part on his or her representations set forth in this section.

(b) If he or she is deemed an affiliate within the meaning of Rule 144 of the Act, the shares of Common Stock must be held indefinitely unless an exemption from any applicable resale restrictions is available or the Company files an additional registration statement (or a “re-offer prospectus”) with regard to such shares of Common Stock and the Company is under no obligation to register the shares of Common Stock (or to file a “re-offer prospectus”).

(c) If he or she is deemed an affiliate within the meaning of Rule 144 of the Act, he or she understands that the exemption from registration under Rule 144 will not be available unless (i) a public trading market then exists for the Common Stock of the Company, (ii) adequate information concerning the Company is then available to the public, and (iii) other terms and conditions of Rule 144 or any exemption therefrom are complied with; and that any sale of the shares of Common Stock may be made only in limited amounts in accordance with such terms and conditions.

13. Transfer of Personal Data. The Participant authorizes, agrees and unambiguously consents to the transmission and processing by the Company (or any Subsidiary) of any personal data information related to Restricted Stock Units awarded under this Agreement, for legitimate business purposes (including, without limitation, the administration of the Plan) out of the Participant’s home country and including to countries with less data protection laws than the data protection laws provided by the Participant’s home country. This authorization/consent is freely given by the Participant.

14. Delivery Delay. The delivery of any certificate representing the Common Stock may be postponed by the Company for such period as may be required for it to comply with any applicable foreign, federal, state or provincial securities law, or any national securities exchange listing requirements and the Company is not obligated to issue or deliver any securities if, in the opinion of counsel for the Company, the issuance of such shares of Common Stock shall constitute a violation by the Participant or the Company of any provisions of any applicable foreign, federal, state or provincial law or of any regulations of any governmental authority or any national securities exchange. The Participant acknowledges and understands that the Company intends to meet its delivery obligations in Common Stock with respect to Restricted Stock Units, except as may be prohibited by law or described in this Agreement, the Plan or supplementary materials.

15. Miscellaneous.

This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, legal representatives, successors and assigns.

(a) Governing Law. This Agreement shall be governed and construed in accordance with the laws of New York (regardless of the law that might otherwise govern under applicable New York principles of conflict of laws).

(b) Counterparts. This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one contract.

(c) Waiver. The failure of any party hereto at any time to require performance by another party of any provision of this Agreement shall not affect the right of such party to require performance of that provision, and any waiver by any party of any breach of any provision of this Agreement shall not be construed as a waiver of any continuing or succeeding breach of such provision, a waiver of the provision itself, or a waiver of any right under this Agreement.

(d) Joint Venture/Partnership. This Agreement and the Plan do not create a joint venture or partnership between the Company and any Subsidiary.

(e) Notwithstanding any provisions in this Agreement, this grant of Restricted Stock Units shall be subject to any additional country-specific and state-specific terms and conditions set forth in Annex 1 to the Agreement for the Participant’s country or state to the extent applicable. Moreover, if the Participant relocates to one of the countries included in Annex 1, the additional country-specific terms and conditions for such country or the additional state-specific terms and conditions for such state, if any, will apply to the Participant to the extent that the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.

16. ACQUIRED RIGHTS. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT: (A) THE COMPANY MAY TERMINATE OR AMEND THE PLAN AT ANY TIME; (B) THE AWARD OF RESTRICTED STOCK UNITS MADE UNDER THIS AGREEMENT IS COMPLETELY INDEPENDENT OF ANY OTHER AWARD OR GRANT AND IS MADE AT THE SOLE DISCRETION OF THE COMPANY; AND (C) NO PAST GRANTS OR AWARDS (INCLUDING, WITHOUT LIMITATION, THE RESTRICTED STOCK UNITS AWARDED HEREUNDER) GIVE THE PARTICIPANT ANY RIGHT TO ANY GRANTS OR AWARDS IN THE FUTURE WHATSOEVER.

 

5


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first set forth above.

 

HENRY SCHEIN, INC.

 

Michael S. Ettinger
Executive Vice President, Chief Operating Officer
PARTICIPANT
[Electronic Signature]
 

[Participant Name]

[Acceptance Date]

 

 

 

6


ANNEX 1

Additional Country Specific Terms and Conditions

for the Restricted Stock Unit Agreement

Capitalized terms, unless explicitly defined in this Annex 1, shall have the meanings given to them in the Agreement or in the Plan.

For purposes of this Annex 1, “Employer” means the entity (the Company or Subsidiary) that employs the Participant.

Terms and Conditions

This Annex 1 includes special terms and conditions applicable to the Participant if the Participant resides in one of the countries listed below. These terms and conditions are in addition to or, if so indicated, in place of, the terms and conditions set forth in the Agreement. If the Participant is a citizen or resident (or is considered as such for local law purposes) of a country other than the country in which the Participant is currently residing and/or working, or if the Participant transfers employment and/or residency between countries after the Grant Date, the Company will, in its discretion, determine to what extent the special terms and conditions contained herein shall be applicable to the Participant.

Notifications

This Annex 1 also includes country-specific information of which the Participant should be aware with respect to the Participant’s participation in the Plan. The information is based on the exchange control, foreign asset/account reporting and other laws in effect in the respective countries as of December 2024. Such laws are often complex and change frequently. As a result, the Company strongly recommends that the Participant does not rely on the information noted herein as the only source of information relating to the consequences of his/her participation in the Plan because the information may be out of date at the time that the Participant vests in the Restricted Stock Units or sells the shares of Common Stock acquired under the Plan.

In addition, the information contained herein is general in nature and may not apply to the Participant’s particular situation, and the Company is not in a position to assure the Participant of any particular result. Accordingly, the Participant should seek appropriate professional advice as to how the relevant laws in the Participant’s country may apply to his/her individual situation.

The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Participant’s participation in the Plan, or the Participant’s acquisition or sale of the underlying shares of Common Stock. The Participant should consult with his/her own personal tax, legal and financial advisors regarding his/her participation in the Plan before taking any action related to the Plan.

Finally, if the Participant is a citizen or resident (or is considered as such for local tax purposes) of a country other than the one in which the Participant is currently residing and/or working, or if the Participant transfers employment and/or residency after the Grant Date, the information contained herein may not be applicable to the Participant in the same manner.

 

7


UNITED STATES

The second to last sentence of Section 2(d) of Agreement is hereby deleted in its entirety and replaced with the following:

“For the purposes of this Agreement, a “Change of Control” shall mean the occurrence of a Section 409A Change of Control (as defined in Section 17).”

As of the Grant Date, if the Participant either (i) qualifies for Retirement (as defined in Section 2(c) of the Agreement) or (ii) may become eligible to qualify for Retirement prior to the applicable Scheduled Payment Date, Section 4 of the Agreement is hereby deleted in its entirety and replaced with the following:

Dividend Equivalents. Cash dividends on Shares shall be credited to a dividend book entry account on behalf of the Participant with respect to each Restricted Stock Unit granted to the Participant, provided that such cash dividends shall not be deemed to be reinvested in Shares and will be held uninvested and without interest. The Participant’s right to receive any such cash dividends shall vest if and when the related Restricted Stock Unit vests, and such cash dividends shall be paid in cash to the Participant if and when the related Restricted Stock Unit is paid to the Participant. Stock dividends on Shares shall be credited to a dividend book entry account on behalf of the Participant with respect to each Restricted Stock Unit granted to the Participant. The Participant’s right to receive any such stock dividends shall vest if and when the related Restricted Stock Unit vests, and such stock dividends shall be paid in stock to the Participant if and when the related Restricted Stock Unit is paid to the Participant.”

The following shall be added to the Agreement as a new Section 17:

Change of Control Defined. For purposes of this Agreement, a “Section 409A Change of Control” shall be deemed to have occurred upon:

(i) an acquisition by any Person of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Act) of (A) 50% or more of the then outstanding Shares or (B) 33% or more of the total combined voting power of the then outstanding voting securities of HSI entitled to vote generally in the election of directors (the “Outstanding HSI Voting Securities”); excluding, however, the following: (w) any acquisition directly from the Company, other than an acquisition by virtue of the exercise of a conversion privilege unless the security being so converted was itself acquired directly from the Company, (x) any acquisition by the Company, (y) any acquisition by an employee benefit plan (or related trust) sponsored or maintained by the Company or (z) any acquisition by any corporation pursuant to a reorganization, merger, consolidation or similar corporate transaction (in each case, a “Corporate Transaction”), if, pursuant to such Corporate Transaction, the conditions described in clauses (A), (B) and (C) of paragraph (iii) below are satisfied; or

(ii) within any 12-month period beginning on or after the date of the Agreement, the individuals who constitute the Board immediately before the beginning of such period (the Board as of the date hereof shall be hereinafter referred to as the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided that for purposes of this Subsection any individual who becomes a member of the Board subsequent to the date hereof whose election, or nomination for election by HSI’s stockholders, was approved by a vote of at least a majority of those individuals who are members of the Board and who are also members of the Incumbent Board (or deemed to be such pursuant to this proviso) shall be considered as though such individual were a member of the Incumbent Board; but, provided further, that any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board shall not be so considered as a member of the Incumbent Board; or

 

8


(iii) the consummation of a Corporate Transaction or, if consummation of such Corporate Transaction is subject to the consent of any government or governmental agency, the obtaining of such consent (either explicitly or implicitly by consummation); excluding, however, such a Corporate Transaction pursuant to which (A) all or substantially all of the individuals and entities who are the beneficial owners, respectively, of the outstanding Shares and Outstanding HSI Voting Securities immediately prior to such Corporate Transaction will beneficially own, directly or indirectly, more than 60% of, respectively, the outstanding shares of common stock of the corporation resulting from such Corporate Transaction and the combined voting power of the outstanding voting securities of such corporation entitled to vote generally in the election of directors, in substantially the same proportions as their ownership, immediately prior to such Corporate Transaction, of the outstanding Shares and Outstanding HSI Voting Securities, as the case may be, (B) no Person (other than the Company, any employee benefit plan (or related trust) of the Company or the corporation resulting from such Corporate Transaction and any Person beneficially owning, immediately prior to such Corporate Transaction, directly or indirectly, 33% or more of the outstanding Shares or Outstanding HSI Voting Securities, as the case may be, will beneficially own, directly or indirectly, 33% or more of, respectively, the outstanding shares of common stock of the corporation resulting from such Corporate Transaction or the combined voting power of the then outstanding securities of such corporation entitled to vote generally in the election of directors and (C) individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors of the corporation resulting from such Corporate Transaction; or

(iv) the sale or other disposition of all or substantially all of the assets of the Company; excluding, however, such sale or other disposition to a corporation with respect to which, following such sale or other disposition, (x) more than 60% of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors will be then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the outstanding Common Stock and Outstanding HSI Voting Securities immediately prior to such sale or other disposition in substantially the same proportion as their ownership, immediately prior to such sale or other disposition, of the outstanding Common Stock and Outstanding HSI Voting Securities, as the case may be, (y) no Person (other than the Company and any employee benefit plan (or related trust) of the Company or such corporation and any Person beneficially owning, immediately prior to such sale or other disposition, directly or indirectly, 33% or more of the outstanding Common Stock or Outstanding HSI Voting Securities, as the case may be) will beneficially own, directly or indirectly, 33% or more of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors and (z) individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors of such corporation.

(v) No event set forth herein shall constitute a “Section 409A Change of Control” unless such event also qualifies as a “change in control event” for purposes of Treasury Regulation § 1.409A-3(i)(5). Accordingly, the definition of “Section 409A Change of Control” set forth herein shall be limited, construed and interpreted in accordance with Section 409A and the regulations issued thereunder.”

 

9


The following shall be added to the Agreement as a new Section 18:

Section 409A. This Agreement is subject to Section 16(i) of the Plan, and any provisions in this Agreement providing for the payment of “nonqualified deferred compensation” (as defined in Section 409A of the Code and the Treasury regulations thereunder) to the Participant are intended to comply with, or be exempt from, the requirements of Section 409A of the Code, and this Agreement shall be interpreted in accordance therewith. Neither party individually or in combination may accelerate or defer the timing of the payment of any such nonqualified deferred compensation, except in compliance with Section 409A of the Code and this Agreement, and no amount shall be paid prior to the earliest date on which it is permitted to be paid under Section 409A of the Code and this Agreement. In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on the Participant as a result of Section 409A of the Code or any damages for failing to comply with Section 409A of the Code. A Termination of Employment or Retirement shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A of the Code upon or following a Termination of Employment or Retirement, as applicable, unless such Termination of Employment or Retirement, as applicable, is also a “separation from service” within the meaning of Section 409A of the Code and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” If the Participant is a “specified employee,” upon his or her “separation from service” (as defined under Section 409A of the Code under such definitions and procedures as established by the Company in accordance with Section 409A of the Code), any portion of a payment, settlement, or other distribution made upon such a “separation from service” that would cause the acceleration of, or an addition to, any taxes pursuant to Section 409A of the Code will not commence or be paid until a date that is six (6) months and one (1) day following the applicable “separation from service.” Any payments, settlements, or other distributions that are delayed pursuant to this Section 18 following the applicable “separation from service” shall be accumulated and paid to the Participant in a lump sum without interest on the first business day immediately following the required delay period. Any amounts payable hereunder that satisfy the short-term deferral exception in Treas. Reg. §1.409A-1(b)(4) shall not be subject to Section 409A of the Code. Whenever a payment under this Agreement may be paid within a specified period, the actual date of payment within the specified period shall be within the Company’s sole discretion.”

For California Participants only, the following shall be added to the Agreement as a new paragraph immediately following Section

3(d):

FOR CALIFORNIA PARTICIPANTS ONLY. With respect to any Participant who resides, or provides services, in California (a “California Participant”), Section 3(d) does not apply and, for purposes of this Agreement, a California Participant will be deemed to engage in a “Competitive Activity” if, either directly or indirectly, without the express prior written consent of the Company, the Participant (i) prior to a Termination of Employment, takes other employment with, renders services to, or otherwise engages in any business activities with, companies or other entities that are competitors of the Company or any of its affiliates, (ii) prior to a Termination of Employment, solicits or induces, or in any manner attempts to solicit or induce, any person employed by or otherwise providing services to the Company or any of its affiliates, to terminate such person’s employment or service relationship, as the case may be, with the Company or any of its affiliates, (iii) prior to a Termination of Employment, diverts, or attempts to divert, any person or entity from doing business with the Company or any of its affiliates or induces, or attempts to induce, any such person or entity from ceasing to be a customer or other business partner of the Company or any of its affiliates, (iv) violates any agreement between the Participant and the Company or any of its affiliates relating to the non-disclosure of proprietary or confidential information of the Company or any of its affiliates, and/or (v) makes false, misleading or negative statements, either orally or in writing, about the Company or any of its affiliates; provided however, with respect to subsections (iv) and (v), following a Termination of Employment, the Participant will not be limited from engaging in a lawful profession, trade, or business that is competitive with the Company or any of its affiliates or restrained from any activity that would be a violation of California Business and Professions Code § 16600. Any determination as to whether the Participant has failed to earn the Restricted Stock Units (and any payments made with respect thereto) or engaged in a Competitive Activity shall be made (A) if the Participant is an executive officer of the Company, by the Committee in its sole discretion or (B) if the Participant is not an executive officer of the Company, by the Company in its sole discretion.

 

10


With respect to any California Participant, notwithstanding the date of payment, and subject to Section 3, no Restricted Stock Unit (including any dividends credited thereupon and the underlying shares) shall be earned by any Participant prior to the first anniversary date of the Payment Date and satisfaction of the conditions under this Agreement.

 

11

Exhibit 99.2

FORM OF

OPTION AGREEMENT

PURSUANT TO THE

HENRY SCHEIN, INC. 2024 STOCK INCENTIVE PLAN

(AS AMENDED AND RESTATED EFFECTIVE AS OF MAY 21, 2024)

THIS AGREEMENT (the “Agreement”) is made as of [Grant Date] (the “Grant Date”), by and between Henry Schein, Inc. (the “Company”) and [Participant Name] (the “Participant”). Additional country-specific terms and conditions that govern the grant made hereunder are attached hereto on Annex 1, which terms and conditions are incorporated by reference herein and made a part of the Agreement.

Preliminary Statement

The Compensation Committee (the “Committee”) of the Company’s Board of Directors (the “Board”), pursuant to the Henry Schein, Inc. 2024 Stock Incentive Plan (as amended and restated effective as of May 21, 2024) (a copy of which is on file with the Company’s Corporate Human Resources Department and is available for the Participant to review upon request at reasonable intervals as determined by the Company) (the “Plan”), has authorized the grant to the Participant, as a Key Employee of the Company or a Subsidiary, of a nonqualified stock option (the “Option”) to purchase the number of shares of the Company’s Common Stock, par value $0.01 per share, set forth below. The parties hereto desire to enter into this Agreement in order to set forth the terms and conditions of the Option. Capitalized terms used but not defined herein shall have the same meaning as set forth in the Plan.

Accordingly, the parties hereto agree as follows:

A. Tax Matters. No part of the Option granted hereby is intended to qualify as an “incentive stock option” under Section 422 of the Code.

B. Grant of Option. Subject in all respects to the Plan and the terms and conditions set forth herein, the Participant is hereby granted the Option to purchase from the Company up to [number] shares of Common Stock (the “Shares”), at a price per Share of $[option price] (the “Option Price”). Subject to the terms and conditions hereof, the Option may be exercised by the Participant, in whole or in part, at any time or from time to time during the period commencing on the applicable anniversary date (as provided in Section E below) and ending on the expiration of the Option as provided herein.

C. Restriction on Transfer. The Option granted hereby is not transferable otherwise than by will or under the applicable laws of descent and distribution and during the lifetime of the Participant may be exercised only by the Participant or his or her guardian or legal representative. In addition, the Option shall not be assigned, negotiated, pledged or hypothecated in any way (whether by operation of law or otherwise), and the Option shall not be subject to execution, attachment or similar process. Upon any attempt to transfer, assign, negotiate, pledge or hypothecate the Option, or in the event of any levy upon the Option by reason of any execution, attachment or similar process contrary to the provisions hereof, the Option shall immediately become null and void.

D. Term of Option. Unless terminated earlier as provided below or otherwise pursuant to the Plan, the Option shall expire on the tenth anniversary of the Grant Date.

E. Exercise of Option.

1. No part of the Option may be exercised unless and until it has become vested. One-fourth (1/4) of the Option granted hereunder shall automatically and immediately vest on each of the first, second, third and fourth anniversaries of the Grant Date, provided that, subject to Section F hereof, the Participant has not had a Termination of Employment at any time prior to the applicable anniversary date (except as otherwise set forth in an employment agreement between the Company and Participant (if applicable), the Company’s Executive Severance Plan (if applicable), or the Plan).

2. The Option may be exercised by the Participant by delivering notice to the Committee of the election to exercise the Option and of the number of Shares with respect to which the Option is being exercised, which notice shall be accompanied by payment in full for the Shares. Payment for such Shares may be made as follows:

(a) in cash or by certified check, bank draft or money order payable to the order of the Company;

(b) if so permitted by the Committee through the delivery of unencumbered Shares (including Shares acquired upon the Option then being exercised); or

(c) on such terms and conditions as may be acceptable to the Committee and in accordance with applicable law.

3. As soon as practicable following receipt of payment and satisfaction of the requirements, if any, as to withholding of taxes set forth in the Plan, the Company shall cause to be issued in the name of the Participant the Shares then purchased (as evidenced by the appropriate entry on the books of the Company or a duly authorized transfer agent of the Company).

Form 1

3/26


4. The exercise of the Option after Termination of Employment shall be subject to satisfaction of the conditions precedent that the Participant neither take other employment or render services to (a) companies that are competitors of the Company or any of its Subsidiaries, or (b) companies that are competitors of the Company or any of its Subsidiaries so that the Participant’s employment with such company could be prejudicial to the Company or any of its Subsidiaries or in conflict with the interests of the Company or any of its Subsidiaries, without the express prior written consent of the Company, nor conduct himself or herself in a manner adversely affecting the Company or any of its Subsidiaries, including but not limited to making false, misleading or negative statements, either orally or in writing, about the Company or any of its Subsidiaries. If the Participant exercises his or her Option and the Company determines that the Participant subsequently (within a year following Termination of Employment) engages in conduct which would have been subject to this provision had it taken place prior to exercise of the Option, then the Participant hereby agrees to immediately return to the Company any financial benefit he or she received from the Option upon request of the Company.

5. Upon a Change of Control, the Option shall immediately become vested, unless two-thirds of members of the Incumbent Board (as defined in the Plan) has approved the change of control provision, in which event, there shall be no accelerated vesting of the Option.

F. Termination of Employment.

1. Death or Disability. Subject to Section E hereof, upon Termination of Employment by reason of death or Disability, the Option shall become 100% vested and (to the extent then not exercised by the Participant prior to such Termination of Employment) shall remain exercisable by the Participant (or in the case of the Participant’s death, the Participant’s estate or the person given authority to exercise such Option by will or operation of law) for a period of one (1) year from the date of Termination of Employment.

2. Termination Without Cause Within Two Years Following a Change of Control. Subject to Section E hereof, upon Termination of Employment by the Company (or a Subsidiary) without Cause occurring within the 2-year period following a Change of Control; provided that no Termination of Employment has occurred prior to such date, unless otherwise provided expressly in a written agreement between the Participant and the Company (or a Subsidiary), the Option shall become 100% vested and (to the extent then not exercised by the Participant prior to such Termination of Employment) shall remain exercisable by the Participant for a period of three (3) months from the date of Termination of Employment. For purposes of this Agreement, “Cause” shall have the meaning set forth in Section 7(b) of the Plan, but shall also include any breach by the Participant of any agreement with the Company or any of its Subsidiaries. For purposes of this Agreement, a “Change of Control” shall mean the occurrence of a Change of Control (as defined in the Plan).

3. Retirement. Subject to Section E hereof, upon the Participant’s Retirement, unless otherwise provided expressly in a written agreement between the Participant and the Company (or a Subsidiary), the Option shall remain outstanding and shall continue to vest and become exercisable following Retirement in accordance with Section E(1) hereof notwithstanding the Participant’s Retirement and (to the extent then not exercised by the Participant prior to such Termination of Employment) shall remain exercisable by the Participant for the remainder of the Option term set forth in Section D hereof. For purposes of this Agreement, the Participant shall qualify for “Retirement” if (i) the Participant’s age (minimum 55) plus years of service with the Company and its Subsidiaries equal or exceed 70, (ii) the Participant has provided written notice of the Participant’s retirement to the Company at least 30 days prior to the date of such retirement, and (iii) no Termination of Employment has occurred prior to the date of such retirement. For purposes of determining the age and service requirement under Section F(3), the Participant’s age and years of service shall be determined by the Participant’s most recent birthday and employment anniversary, respectively.

4. Cause. Upon a Participant’s Termination of Employment for Cause, or by the Participant in violation of a written agreement between the Participant and the Company or any Subsidiary thereof, or if it is discovered that after such Termination of Employment that the Participant is engaged in conduct that would have justified a Termination of Employment for Cause, the entire outstanding Option shall automatically be canceled. In addition, upon any such Termination of Employment the Committee may, in its discretion, require the Participant to promptly pay to the Company (and the Company shall have the right to recover) any gain the Participant realized as a result of the exercise of the Option that occurred within one (1) year prior to such Termination of Employment or the discovery of conduct that would have justified a Termination of Employment for Cause.

5. Other Termination. In the event of Termination of Employment for any reason other than as provided in Sections F(1), F(2), F(3) or F(4), the vested portion of the Option not exercised by the Participant prior to such Termination of Employment shall remain exercisable (to the extent exercisable by such Participant immediately before such termination) for a period of three (3) months from the date of Termination of Employment. Any portion of the Option that is not yet exercisable on the date of Termination of Employment because of vesting provisions or otherwise shall be canceled.

 

2

Form 1

3/26


6. Forfeiture; Recoupment.

(a) If, during the twelve-month period following the Participant’s Termination of Employment for any reason, the Participant engages in a Competitive Activity (as defined below), the Committee shall have the right, in its sole discretion, to cause the immediate forfeiture of all of the unexercised Option in its entirety, in which case the Participant shall have no further rights or interests with respect to such Option, and the Company shall also have the right to recoup from the Participant, and the Participant shall repay to the Company, within thirty (30) days following demand by the Company, a payment equal to the Fair Market Value of the aggregate Shares received upon exercise of the Option (if any), net of the aggregate exercise price paid by the Participant in cash upon exercise of such Option (if any); provided, that, the Company may require the Participant to satisfy such payment obligations hereunder either by forfeiting and returning to the Company such Shares received upon exercise of the Option or any other Shares, or making a cash payment or any combination of these methods, as determined by the Company in its sole discretion. The Company and its Subsidiaries, in their sole discretion, shall have the right to set off (or cause to be set off) any amounts otherwise due to the Participant from the Company (or the applicable Subsidiary) in satisfaction of such repayment obligation, provided that any such amounts are exempt from, or set off in a manner intended to comply with, the requirements of any applicable law (including, without limitation, Section 409A of the Code).

(b) The Participant hereby acknowledges and agrees that the forfeiture and recoupment conditions set forth in this Sections E and F, in view of the nature of the business in which the Company and its affiliates are engaged, are reasonable in scope and necessary in order to protect the legitimate business interests of the Company and its affiliates, and that any violation thereof would result in irreparable harm to the Company and its affiliates. The Participant also acknowledges and agrees that (i) it is a material inducement and condition to the Company’s issuance of the Option that such Participant agrees to be bound by such forfeiture and recoupment conditions and, further, that the amounts required to be forfeited or repaid to the Company pursuant to forfeiture and recoupment conditions set forth above are reasonable, and (ii) nothing in this Agreement or the Plan is intended to preclude the Company (or any affiliate thereof) from seeking any remedies available at law, in equity, under contract to the Company or otherwise, and the Company (or any affiliate thereof) shall have the right to seek any such remedy with respect to the Option, or otherwise.

(c) For purposes of this Agreement, the Participant will be deemed to engage in a “Competitive Activity” if, either directly or indirectly, without the express prior written consent of the Company, the Participant (i) takes other employment with, renders services to, or otherwise engages in any business activities with, companies or other entities that are competitors of the Company or any of its affiliates, (ii) solicits or induces, or in any manner attempts to solicit or induce, any person employed by or otherwise providing services to the Company or any of its affiliates, to terminate such person’s employment or service relationship, as the case may be, with the Company or any of its affiliates, (iii) diverts, or attempts to divert, any person or entity from doing business with the Company or any of its affiliates or induces, or attempts to induce, any such person or entity from ceasing to be a customer or other business partner of the Company or any of its affiliates, (iv) violates any agreement between the Participant and the Company or any of its affiliates relating to the non-disclosure of proprietary or confidential information of the Company or any of its affiliates, and/or (v) conducts himself or herself in a manner adversely affecting the Company or any of its affiliates, including, without limitation, making false, misleading or negative statements, either orally or in writing, about the Company or any of its affiliates. The determination as to whether the Participant has engaged in a Competitive Activity shall be made by the Committee in its sole discretion.

(d) This Section F(6)(d) applies solely with respect to Participants who are members of the Company’s Executive Management Committee. Notwithstanding anything herein to the contrary, the Participant agrees and acknowledges that the Option awarded under this Agreement and the underlying shares shall be subject to the terms and conditions of the Company’s Incentive Compensation Recoupment Policy approved by the Board. Notwithstanding the foregoing, the Participant agrees that incentive compensation, as defined under of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and such regulations as are promulgated thereunder from time to time (“Dodd-Frank”), payable to the Participant under this Agreement shall be subject to any clawback policy adopted or implemented by the Company in respect of Dodd-Frank, or in respect of any other applicable law or regulation.

G. Rights as a Stockholder. The Participant shall have no rights as a stockholder with respect to any Shares covered by the Option until the Participant shall have become the holder of record of the Shares, and no adjustments shall be made for dividends in cash or other property, distributions or other rights in respect of any such Shares, except as otherwise specifically provided for in this Agreement or the Plan.

 

 

3

Form 1

3/26


H. Provisions of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan, including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. Subject to Section F, if and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes any prior agreements between the Company and the Participant with respect to the subject matter hereof.

I. Amendment. To the extent applicable, the Board or the Committee may at any time and from time to time amend, in whole or in part, any or all of the provisions of this Agreement to comply with any applicable laws and stock exchange rules and regulations (including, without limitation, Section 409A of the Code and the regulations thereunder) and may also amend, suspend or terminate this Agreement subject to the terms of the Plan. Except as otherwise provided in the Plan, no modification or waiver of any of the provisions of this Agreement shall be effective unless in writing and signed by the party against whom it is sought to be enforced.

J. Notices. Any notice or communication given hereunder shall be in writing and shall be deemed to have been duly given when delivered in person, or by regular United States mail or similar foreign mail or post, first class and prepaid, to the appropriate party at the address set forth below (or such other address as the party shall from time to time specify):

If to the Company, to:

Henry Schein, Inc.

135 Duryea Road

Melville, New York 11747

Attention: General Counsel

If to the Participant, to the address on file with the Company.

K. No Obligation to Continue Employment or Services. This Agreement is not an agreement of employment, consultancy or directorship. This Agreement does not guarantee that the Company or its Subsidiaries will employ or retain, or continue to employ or retain, the Participant during the entire, or any portion of the, term of this Agreement, including but not limited to any period during which any Option is outstanding, nor does it modify in any respect the Company or its Subsidiaries’ right to terminate or modify the Participant’s employment, service relationship or compensation.

L. Dividend Equivalents. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends (except as provided in Section 5(d) of the Plan) or any other rights as a stockholder will exist with respect to the Shares subject to the Option, notwithstanding the exercise of the Option. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 5(d) of the Plan. No dividend equivalents shall be issued or paid with respect to any Option.

M. Withholding. The Participant shall pay, or make arrangements to pay, in a manner satisfactory to the Company, an amount equal to the amount of all applicable foreign, federal, state, provincial and local taxes that the Company is required to withhold at any time. In the absence of such arrangements, the Company or one of its Subsidiaries shall have the right to withhold such taxes from the Participant’s normal pay or other amounts payable to the Participant. In addition, any statutorily required withholding obligation may be satisfied, in whole or in part, at the Participant’s election, in the form and manner prescribed by the Committee, by delivery of Shares (including Shares issuable under this Agreement).

N. Legend. The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates representing Shares issued pursuant to this Agreement. The Participant shall, at the request of the Company, promptly present to the Company any and all certificates representing Shares acquired pursuant to this Agreement in the possession of the Participant in order to carry out the provisions of this Section.

O. Transfer of Personal Data. The Participant authorizes, agrees and unambiguously consents to the transmission and processing by the Company (or any Subsidiary) of any personal data information related to Option awarded under this Agreement, for legitimate business purposes (including, without limitation, the administration of the Plan) out of the Participant’s home country and including to countries with less data protection laws than the data protection laws provided by the Participant’s home country. This authorization/consent is freely given by the Participant.

P. Delivery Delay. The delivery of any certificate representing the Common Stock may be postponed by the Company for such period as may be required for it to comply with any applicable foreign, federal, state or provincial securities law, or any national securities exchange listing requirements and the Company is not obligated to issue or deliver any securities if, in the opinion of counsel for the Company, the issuance of such Shares shall constitute a violation by the Participant or the Company of any provisions of any applicable foreign, federal, state or provincial law or of any regulations of any governmental authority or any national securities exchange. The Participant acknowledges and understands that the Company intends to meet its delivery obligations in Common Stock with respect to the Option, except as may be prohibited by law or described in this Agreement, the Plan or supplementary materials.

 

4

Form 1

3/26


Q. Miscellaneous.

This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, legal representatives, successors and assigns.

1. This Agreement shall be governed and construed in accordance with the laws of New York (regardless of the law that might otherwise govern under applicable New York principles of conflict of laws).

2. This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one contract.

3. The failure of any party hereto at any time to require performance by another party of any provision of this Agreement shall not affect the right of such party to require performance of that provision, and any waiver by any party of any breach of any provision of this Agreement shall not be construed as a waiver of any continuing or succeeding breach of such provision, a waiver of the provision itself, or a waiver of any right under this Agreement.

4. This Agreement and the Plan do not create a joint venture or partnership between the Company and any Subsidiary.

5. Notwithstanding any provisions in this Agreement, this grant of the Option shall be subject to any additional country-specific terms and conditions set forth in Annex 1 to the Agreement for the Participant’s country to the extent applicable. Moreover, if the Participant relocates to one of the countries included in Annex 1, the additional country-specific terms and conditions for such country, if any, will apply to the Participant to the extent that the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.

R. ACQUIRED RIGHTS. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT: (A) THE COMPANY MAY TERMINATE OR AMEND THE PLAN AT ANY TIME; (B) THE AWARD OF THE OPTION MADE UNDER THIS AGREEMENT IS COMPLETELY INDEPENDENT OF ANY OTHER AWARD OR GRANT AND IS MADE AT THE SOLE DISCRETION OF THE COMPANY; AND (C) NO PAST GRANTS OR AWARDS (INCLUDING, WITHOUT LIMITATION, THE OPTION AWARDED HEREUNDER) GIVE THE PARTICIPANT ANY RIGHT TO ANY GRANTS OR AWARDS IN THE FUTURE WHATSOEVER.

IN WITNESS WHEREOF, the parties have executed this Agreement on the date and year first above written.

 

HENRY SCHEIN, INC.

 

Michael S. Ettinger
Executive Vice President, Chief Operating Officer
PARTICIPANT
[Electronic Signature]
 

[Participant Name]

[Acceptance Date]

 

 

 

5

Form 1

3/26


ANNEX 1

Additional Country Specific Terms and Conditions

for the Option Agreement

Capitalized terms, unless explicitly defined in this Annex 1, shall have the meanings given to them in the Agreement or in the Plan.

For purposes of this Annex 1, “Employer” means the entity (the Company or Subsidiary) that employs the Participant.

Terms and Conditions

This Annex 1 includes special terms and conditions applicable to the Participant if the Participant resides in one of the countries listed below. These terms and conditions are in addition to or, if so indicated, in place of, the terms and conditions set forth in the Agreement. If the Participant is a citizen or resident (or is considered as such for local law purposes) of a country other than the country in which the Participant is currently residing and/or working, or if the Participant transfers employment and/or residency between countries after the Grant Date, the Company will, in its discretion, determine to what extent the special terms and conditions contained herein shall be applicable to the Participant.

Notifications

This Annex 1 also includes country-specific information of which the Participant should be aware with respect to the Participant’s participation in the Plan. The information is based on the exchange control, foreign asset/account reporting and other laws in effect in the respective countries as of April 2021. Such laws are often complex and change frequently. As a result, the Company strongly recommends that the Participant does not rely on the information noted herein as the only source of information relating to the consequences of his/her participation in the Plan because the information may be out of date at the time that the Participant vests in and exercises the Option and acquires Shares or sells the Shares acquired under the Plan.

In addition, the information contained herein is general in nature and may not apply to the Participant’s particular situation, and the Company is not in a position to assure the Participant of any particular result. Accordingly, the Participant should seek appropriate professional advice as to how the relevant laws in the Participant’s country may apply to his/her individual situation.

The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Participant’s participation in the Plan, or the Participant’s acquisition or sale of the underlying Shares. The Participant should consult with his/her own personal tax, legal and financial advisors regarding his/her participation in the Plan before taking any action related to the Plan.

Finally, if the Participant is a citizen or resident (or is considered as such for local tax purposes) of a country other than the one in which the Participant is currently residing and/or working, or if the Participant transfers employment and/or residency after the Grant Date, the information contained herein may not be applicable to the Participant in the same manner.

 

6

Form 1

3/26


UNITED STATES

The last sentence of Section F(2) of Agreement is hereby deleted in its entirety and replaced with the following:

“For the purposes of this Agreement, a “Change of Control” shall mean the occurrence of a Section 409A Change of Control (as defined in Section S).”

The following shall be added to the Agreement as a new Section S:

Change of Control Defined. For purposes of this Agreement, a “Section 409A Change of Control” shall be deemed to have occurred upon:

(i) an acquisition by any Person of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Act) of (A) 50% or more of the then outstanding Shares or (B) 33% or more of the total combined voting power of the then outstanding voting securities of HSI entitled to vote generally in the election of directors (the “Outstanding HSI Voting Securities”); excluding, however, the following: (w) any acquisition directly from the Company, other than an acquisition by virtue of the exercise of a conversion privilege unless the security being so converted was itself acquired directly from the Company, (x) any acquisition by the Company, (y) any acquisition by an employee benefit plan (or related trust) sponsored or maintained by the Company or (z) any acquisition by any corporation pursuant to a reorganization, merger, consolidation or similar corporate transaction (in each case, a “Corporate Transaction”), if, pursuant to such Corporate Transaction, the conditions described in clauses (A), (B) and (C) of paragraph (iii) below are satisfied; or

(ii) within any 12-month period beginning on or after the date of the Agreement, the individuals who constitute the Board immediately before the beginning of such period (the Board as of the date hereof shall be hereinafter referred to as the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided that for purposes of this Subsection any individual who becomes a member of the Board subsequent to the date hereof whose election, or nomination for election by HSI’s stockholders, was approved by a vote of at least a majority of those individuals who are members of the Board and who are also members of the Incumbent Board (or deemed to be such pursuant to this proviso) shall be considered as though such individual were a member of the Incumbent Board; but, provided further, that any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board shall not be so considered as a member of the Incumbent Board; or

(iii) the consummation of a Corporate Transaction or, if consummation of such Corporate Transaction is subject to the consent of any government or governmental agency, the obtaining of such consent (either explicitly or implicitly by consummation); excluding, however, such a Corporate Transaction pursuant to which (A) all or substantially all of the individuals and entities who are the beneficial owners, respectively, of the outstanding Shares and Outstanding HSI Voting Securities immediately prior to such Corporate Transaction will beneficially own, directly or indirectly, more than 60% of, respectively, the outstanding Shares of the corporation resulting from such Corporate Transaction and the combined voting power of the outstanding voting securities of such corporation entitled to vote generally in the election of directors, in substantially the same proportions as their ownership, immediately prior to such Corporate Transaction, of the outstanding Shares and Outstanding HSI Voting Securities, as the case may be, (B) no Person (other than the Company, any employee benefit plan (or related trust) of the Company or the corporation resulting from such Corporate Transaction and any Person beneficially owning, immediately prior to such Corporate Transaction, directly or indirectly, 33% or more of the outstanding Shares or Outstanding HSI Voting Securities, as the case may be, will beneficially own, directly or indirectly, 33% or more of, respectively, the outstanding Shares of the corporation resulting from such Corporate Transaction or the combined voting power of the then outstanding securities of such corporation entitled to vote generally in the election of directors and (C) individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors of the corporation resulting from such Corporate Transaction; or

(iv) the sale or other disposition of all or substantially all of the assets of the Company; excluding, however, such sale or other disposition to a corporation with respect to which, following such sale or other disposition, (x) more than 60% of, respectively, the then outstanding Shares of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors will be then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the outstanding Common Stock and Outstanding HSI Voting Securities immediately prior to such sale or other disposition in substantially the same proportion as their ownership, immediately prior to such sale or other disposition, of the outstanding Common Stock and Outstanding HSI Voting Securities, as the case may be, (y) no Person (other than the Company and any employee benefit plan (or related trust) of the

 

7

Form 1

3/26


Company or such corporation and any Person beneficially owning, immediately prior to such sale or other disposition, directly or indirectly, 33% or more of the outstanding Common Stock or Outstanding HSI Voting Securities, as the case may be) will beneficially own, directly or indirectly, 33% or more of, respectively, the then outstanding Shares of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors and (z) individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors of such corporation.

(v) No event set forth herein shall constitute a “Section 409A Change of Control” unless such event also qualifies as a “change in control event” for purposes of Treasury Regulation § 1.409A-3(i)(5). Accordingly, the definition of “Section 409A Change of Control” set forth herein shall be limited, construed and interpreted in accordance with Section 409A and the regulations issued thereunder.”

The following shall be added to the Agreement as a new Section T:

Section 409A. This Agreement is subject to Section 16(i) of the Plan, and any provisions in this Agreement providing for the payment of “nonqualified deferred compensation” (as defined in Section 409A of the Code and the Treasury regulations thereunder) to the Participant are intended to comply with, or be exempt from, the requirements of Section 409A of the Code, and this Agreement shall be interpreted in accordance therewith. Neither party individually or in combination may accelerate or defer the timing of the payment of any such nonqualified deferred compensation, except in compliance with Section 409A of the Code and this Agreement, and no amount shall be paid prior to the earliest date on which it is permitted to be paid under Section 409A of the Code and this Agreement. In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on the Participant as a result of Section 409A of the Code or any damages for failing to comply with Section 409A of the Code. A Termination of Employment or Retirement shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A of the Code upon or following a Termination of Employment or Retirement, as applicable, unless such Termination of Employment or Retirement, as applicable, is also a “separation from service” within the meaning of Section 409A of the Code and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” If the Participant is a “specified employee,” upon his or her “separation from service” (as defined under Section 409A of the Code under such definitions and procedures as established by the Company in accordance with Section 409A of the Code), any portion of a payment, settlement, or other distribution made upon such a “separation from service” that would cause the acceleration of, or an addition to, any taxes pursuant to Section 409A of the Code will not commence or be paid until a date that is six (6) months and one (1) day following the applicable “separation from service.” Any payments, settlements, or other distributions that are delayed pursuant to this Section 18 following the applicable “separation from service” shall be accumulated and paid to the Participant in a lump sum without interest on the first business day immediately following the required delay period. Any amounts payable hereunder that satisfy the short-term deferral exception in Treas. Reg. §1.409A-1(b)(4) shall not be subject to Section 409A of the Code. Whenever a payment under this Agreement may be paid within a specified period, the actual date of payment within the specified period shall be within the Company’s sole discretion.”

 

8

Form 1

3/26

Exhibit 99.3

FORM OF

RESTRICTED STOCK UNIT AGREEMENT

PURSUANT TO THE

HENRY SCHEIN, INC. 2023 NON-EMPLOYEE DIRECTOR STOCK INCENTIVE PLAN

(AS AMENDED AND RESTATED EFFECTIVE AS OF May 23, 2023)

THIS AGREEMENT (the “Agreement”) made as of [Grant Date] (the “Grant Date”), by and between Henry Schein, Inc. (the “Company”) and [Participant Name] (the “Participant”).

W I T N E S S E T H:

WHEREAS, the Company has adopted the Henry Schein, Inc. 2023 Non-Employee Director Stock Incentive Plan (as amended and restated effective as of May 23, 2023), a copy of which is on file with the Company’s Corporate Human Resources Department and is available for Participant to review upon request at reasonable intervals as determined by the Company (the “Plan”), which is administered by a Committee appointed by the Company’s Board of Directors (the “Committee”); and

WHEREAS, pursuant to Section 7 of the Plan, the Committee may grant Restricted Stock Units to non-employee directors under the Plan; and

WHEREAS, the Participant is a non-employee director of the Company.

NOW, THEREFORE, for and in consideration of the mutual promises herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. Grant of Restricted Stock Units. Subject to the restrictions and other conditions set forth herein and in the Plan, the Committee has authorized this grant of [Shares Granted] Restricted Stock Units to the Participant on the Grant Date.

2. Vesting and Payment.

(a) Except as set forth in Sections 2(c) and 2(d) below, the Restricted Stock Units shall vest on the twelve-month anniversary of the Grant Date (the “Scheduled Payment Date”); provided that the Participant has not had a Termination of Services any time prior to the Scheduled Payment Date.

(b) Except as may otherwise be provided by the Committee, in its sole and absolute discretion, there shall be no proportionate or partial vesting in the periods prior to the Scheduled Payment Date and, except as set forth in Sections 2(c) and 2(d) below, all vesting shall occur only on the Scheduled Payment Date; provided that no Termination of Services has occurred prior to the Scheduled Payment Date.

(c) The Restricted Stock Units will become fully vested on a Change of Control; provided that no Termination of Services has occurred prior to the Change of Control. For purposes of vesting, a “Change of Control” shall mean the occurrence of a Change of Control (as defined in the Plan) or a Section 409A Change of Control (as defined in Section 3(f)).

(d) The Restricted Stock Units will become fully vested (i) immediately prior to Participant no longer serving as Non-Executive Chair of the Company’s Board of Directors or (ii) on the date of the Participant’s Retirement. For purposes of this Agreement, “Retirement” shall refer to the Participant’s Termination of Services due to retirement in accordance with the terms and conditions of the Company’s Retirement Policy, approved by the Company’s Board of Directors on November 30, 2015.

(e) The Participant shall be entitled to receive one share of Common Stock with respect to one vested Restricted Stock Unit. The Participant shall be paid one share of Common Stock with respect to each vested Restricted Stock Unit within thirty (30) days of the Scheduled Payment Date; except that, in the event of (i) a Change of Control or (ii) Retirement, the Participant shall be paid within thirty (30) days of such Change of Control or Retirement; provided no Termination of Employment has occurred prior to such dates.

3/26

Form 6-SB


3. Deferred Payment. Notwithstanding Section 2(e) above, the Participant may elect to defer the payment date of his or her vested Restricted Stock Units beyond the Scheduled Payment Date (such elected deferred payment date, the “Deferred Payment Date”), provided, that:

(a) In order for a deferral election under this Section 3 to be effective, the Participant must make the election prior to the Grant Date.

(b) A deferral election made by the Participant pursuant to this Section 3 with respect to one or more of the Participant’s Restricted Stock Units shall, subject to Sections 3(c) and (e) below, defer the payment date of such Restricted Stock Units to the Deferred Payment Date elected by the Participant, which must be one of the following: (i) the third (3rd) anniversary of the Scheduled Payment Date; (ii) the fifth (5th) anniversary of the Scheduled Payment Date; (iii) the seventh (7th) anniversary of the Scheduled Payment Date; (iv) the tenth (10th) anniversary of the Scheduled Payment Date; or (v) the date of the Participant’s Termination of Services which occurs after the Scheduled Payment Date.

(c) The Participant shall also be permitted to further defer the payment date of his or her vested Restricted Stock Units beyond the Deferred Payment Date, provided that: (i) in order to be effective, the Participant must make such deferral election at least twelve (12) months prior to the Deferred Payment Date; (ii) a deferral election made by the Participant pursuant to this Section 3(c) shall defer the payment date of his or her vested Restricted Stock Units for a period of time (expressed in whole years) of not less than five (5) years and no more than ten (10) years beyond the Deferred Payment Date; and (iii) the Participant’s deferral election shall not become effective until twelve (12) months after the date on which it is made. The Participant shall be entitled to make more than one deferral election under this Section 3(c) with respect to his or her vested Restricted Stock Units, and any such new Deferred Payment Date election that becomes effective in accordance herewith shall supersede any previous Deferred Payment Date election made by the Participant with respect to such Restricted Stock Units on and after the twelve (12) month anniversary after the election is made.

(d) The Participant must make any deferral election permitted under this Section 3 in writing on the election form and in accordance with the procedures established by the Company. A deferral election is valid solely with respect to the Restricted Stock Units identified on the election form and must comply with the requirements of this Section 3 to be given effect. Subject to the requirements set forth in this Section 3, the Participant shall be entitled to make deferral elections with respect to all or only a portion of his or her Restricted Stock Units and any such deferral elections need not be the same for all of the Participant’s Restricted Stock Units.

(e) If the Participant elects in accordance with this Section 3 to defer the date of payment of any of his or her Restricted Stock Units beyond the Scheduled Payment Date, the payment date of such Restricted Stock Units, to the extent vested, shall occur within the thirty (30) day period following the earliest of the following to occur: (i) the Deferred Payment Date; (ii) the Participant’s Termination of Services (other than as a result of the Participant’s death, Disability or Retirement), but only if such Termination of Services qualifies as a “separation from service” within the meaning of Section 409A(a)(2)(A)(i) of the Code and the Treasury regulations thereunder and, solely to the extent applicable, subject to the six (6) month delay described in Section 15(h) of the Plan with respect to “specified employees”; (iii) the Participant’s death; (iv) the Participant’s Disability; (v) the Scheduled Payment Date if the Participant has a Termination of Services due to Retirement; or (vi) a “Section 409A Change of Control” (as defined below).

(f) For purposes of Sections 2(c) and 3(e) only, a “Section 409A Change of Control” shall mean a Change in Control (as defined in the Plan); provided, that, no event shall constitute a “Section 409A Change of Control” for purposes of this Agreement unless such event also qualifies as a “change in control event” for purposes of Treasury Regulation § 1.409A-3(i)(5).

 

2

3/26

Form 6-SB


4. Termination.

Except as set forth in Section 2(d) above, all unvested Restricted Stock Units will be forfeited on the Participant’s Termination of Services.

5. Dividend Equivalents. Cash dividends on Shares shall be credited to a dividend book entry account on behalf of the Participant with respect to each Restricted Stock Unit granted to the Participant, provided that such cash dividends shall not be deemed to be reinvested in Shares and will be held uninvested and without interest. The Participant’s right to receive any such cash dividends shall vest if and when the related Restricted Stock Unit vests, and such cash dividends shall be paid in cash to the Participant if and when the related Restricted Stock Unit is paid to the Participant. Stock dividends on Shares shall be credited to a dividend book entry account on behalf of the Participant with respect to each Restricted Stock Unit granted to the Participant. The Participant’s right to receive any such stock dividends shall vest if and when the related Restricted Stock Unit vests, and such stock dividends shall be paid in stock to the Participant if and when the related Restricted Stock Unit is paid to the Participant.

6. Rights as a Stockholder. The Participant shall have no rights as a stockholder with respect to any shares covered by any Restricted Stock Unit unless and until the Participant has become the holder of record of the shares, and no adjustments shall be made for dividends in cash or other property, distributions or other rights in respect of any such shares, except as otherwise specifically provided for in this Agreement or the Plan.

7. Withholding.

To the extent applicable, the Participant shall pay, or make arrangements to pay, in a manner satisfactory to the Company, an amount equal to the amount of all applicable foreign, federal, state, provincial and local taxes that the Company is required to withhold at any time. In the absence of such arrangements, the Company or one of its Subsidiaries shall have the right to withhold such taxes from the Participant’s normal pay or other amounts payable to the Participant. In addition, any statutorily required withholding obligation may be satisfied, in whole or in part, at the Participant’s election, in the form and manner prescribed by the Committee, by delivery of shares of Common Stock (including shares issuable under this Agreement).

8. Provisions of Plan Control. This Agreement is subject to all the terms, conditions and provisions of the Plan, including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan as may be adopted by the Committee and as may be in effect from time to time. The Plan is incorporated herein by reference. Capitalized terms in this Agreement that are not otherwise defined shall have the same meaning as set forth in the Plan. If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and this Agreement shall be deemed to be modified accordingly. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes any prior agreements between the Company and the Participant with respect to the subject matter hereof.

9. Amendment. To the extent applicable, the Board or the Committee may at any time and from time to time amend, in whole or in part, any or all of the provisions of this Agreement to comply with any applicable laws and stock exchange rules and regulations (including, without limitation, Section 409A of the Code and the regulations thereunder) and may also amend, suspend or terminate this Agreement subject to the terms of the Plan. Except as otherwise provided in the Plan, no modification or waiver of any of the provisions of this Agreement shall be effective unless in writing and signed by the party against whom it is sought to be enforced.

10. Notices. Any notice or communication given hereunder shall be in writing and shall be deemed to have been duly given when delivered in person, or by regular United States mail, first class and prepaid, to the appropriate party at the address set forth below (or such other address as the party shall from time to time specify):

If to the Company, to:

Henry Schein, Inc.

135 Duryea Road

Melville, New York 11747

Attention: General Counsel

If to the Participant, to the address on file with the Company.

 

3

3/26

Form 6-SB


11. No Obligation to Continue Directorship. This Agreement is not an agreement of directorship. This Agreement does not guarantee that the Company will retain, or continue to retain, the Participant during the entire, or any portion of the, term of this Agreement, including but not limited to any period during which any Restricted Stock Unit is outstanding, nor does it modify in any respect the Company’s right to terminate or modify the Participant’s services or compensation as a director.

12. Legend. The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates representing Shares issued pursuant to this Agreement. The Participant shall, at the request of the Company, promptly present to the Company any and all certificates representing Shares acquired pursuant to this Agreement in the possession of the Participant in order to carry out the provisions of this Section.

13. Securities Representations. The grant of the Restricted Stock Units and issuance of Shares upon vesting of the Restricted Stock Units shall be subject to, and in compliance with, all applicable requirements of federal, state or foreign securities law. No Shares may be issued hereunder if the issuance of such Shares would constitute a violation of any applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the Shares may then be listed. As a condition to the settlement of the Restricted Stock Units, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation.

The Shares would be issued to the Participant and this Agreement is being made by the Company in reliance upon the following express representations and warranties of the Participant. The Participant acknowledges, represents and warrants that:

(a) He or she has been advised that he or she may be an “affiliate” within the meaning of Rule 144 under the Securities Act of 1933, as amended (the “Act”) and in this connection the Company is relying in part on his or her representations set forth in this section.

(b) If he or she is deemed an affiliate within the meaning of Rule 144 of the Act, the Shares must be held indefinitely unless an exemption from any applicable resale restrictions is available or the Company files an additional registration statement (or a “re-offer prospectus”) with regard to such Shares and the Company is under no obligation to register the Shares (or to file a “re-offer prospectus”).

(c) If he or she is deemed an affiliate within the meaning of Rule 144 of the Act, he or she understands that the exemption from registration under Rule 144 will not be available unless (i) a public trading market then exists for the Common Stock of the Company, (ii) adequate information concerning the Company is then available to the public, and (iii) other terms and conditions of Rule 144 or any exemption therefrom are complied with; and that any sale of the Shares may be made only in limited amounts in accordance with such terms and conditions.

14. Transfer of Personal Data. The Participant authorizes, agrees and unambiguously consents to the transmission and processing by the Company (or any subsidiary) of any personal data information related to the Restricted Stock Units awarded under this Agreement, for legitimate business purposes (including, without limitation, the administration of the Plan) out of the Participant’s home country and including to countries with less data protection laws than the data protection laws provided by the Participant’s home country. This authorization/consent is freely given by the Participant.

15. Section 409A. This Agreement is subject to Section 15(h) of the Plan, and any provisions in this Agreement providing for the payment of “nonqualified deferred compensation” (as defined in Section 409A of the Code and the Treasury regulations thereunder) to the Participant are intended to comply with the requirements of Section 409A of the Code, and this Agreement shall be interpreted in accordance therewith. Neither party individually or in combination may accelerate or defer the timing of the payment of any such nonqualified deferred compensation, except in compliance with Section 409A of the Code and this Agreement, and no amount shall be

 

4

3/26

Form 6-SB


paid prior to the earliest date on which it is permitted to be paid under Section 409A of the Code and this Agreement. In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on the Participant as a result of Section 409A of the Code or any damages for failing to comply with Section 409A of the Code. Any amounts payable hereunder that satisfy the short-term deferral exception in Treas. Reg. §1.409A-1(b)(4) shall not be subject to Section 409A of the Code. Whenever a payment under this Agreement may be paid within a specified period, the actual date of payment within the specified period shall be within the Company’s sole discretion.

16. Miscellaneous. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, legal representatives, successors and assigns.

(a) This Agreement shall be governed and construed in accordance with the laws of New York (regardless of the law that might otherwise govern under applicable New York principles of conflict of laws).

(b) This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one contract.

(c) The failure of any party hereto at any time to require performance by another party of any provision of this Agreement shall not affect the right of such party to require performance of that provision, and any waiver by any party of any breach of any provision of this Agreement shall not be construed as a waiver of any continuing or succeeding breach of such provision, a waiver of the provision itself, or a waiver of any right under this Agreement.

(d) This Agreement and the Plan do not create a joint venture or partnership between the Company and any Subsidiary.

17. NO ACQUIRED RIGHTS. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT: (A) THE COMPANY MAY TERMINATE OR AMEND THE PLAN AT ANY TIME; (B) THE AWARD OF RESTRICTED STOCK UNITS MADE UNDER THIS AGREEMENT IS COMPLETELY INDEPENDENT OF ANY OTHER AWARD OR GRANT AND IS MADE AT THE SOLE DISCRETION OF THE COMPANY; AND (C) NO PAST GRANTS OR AWARDS (INCLUDING, WITHOUT LIMITATION, THE RESTRICTED STOCK UNITS AWARDED HEREUNDER) GIVE THE PARTICIPANT ANY RIGHT TO ANY GRANTS OR AWARDS IN THE FUTURE WHATSOEVER.

 

5

3/26

Form 6-SB


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first set forth above.

 

HENRY SCHEIN, INC.

 

Michael S. Ettinger
Executive Vice President, Chief Operating Officer
PARTICIPANT
[Electronic Signature]
 

[Participant Name]

[Acceptance Date]

 

 

 

6

3/26

Form 6-SB